ID   A0A024RCX5_HUMAN        Unreviewed;       164 AA.
AC   A0A024RCX5;
DT   09-JUL-2014, integrated into UniProtKB/TrEMBL.
DT   09-JUL-2014, sequence version 1.
DT   22-APR-2020, entry version 56.
DE   SubName: Full=Cyclin-dependent kinase inhibitor 1A (P21, Cip1), isoform CRA_a {ECO:0000313|EMBL:EAX03907.1};
GN   Name=CDKN1A {ECO:0000313|EMBL:EAX03907.1};
GN   ORFNames=hCG_15367 {ECO:0000313|EMBL:EAX03907.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:EAX03907.1};
RN   [1] {ECO:0000313|EMBL:EAX03907.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D., Amanatides P.,
RA   Ballew R.M., Huson D.H., Wortman J.R., Zhang Q., Kodira C.D., Zheng X.H.,
RA   Chen L., Skupski M., Subramanian G., Thomas P.D., Zhang J.,
RA   Gabor Miklos G.L., Nelson C., Broder S., Clark A.G., Nadeau J.,
RA   McKusick V.A., Zinder N., Levine A.J., Roberts R.J., Simon M., Slayman C.,
RA   Hunkapiller M., Bolanos R., Delcher A., Dew I., Fasulo D., Flanigan M.,
RA   Florea L., Halpern A., Hannenhalli S., Kravitz S., Levy S., Mobarry C.,
RA   Reinert K., Remington K., Abu-Threideh J., Beasley E., Biddick K.,
RA   Bonazzi V., Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z., Guan P.,
RA   Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A., Lai Z., Lei Y.,
RA   Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V., Milshina N.,
RA   Moore H.M., Naik A.K., Narayan V.A., Neelam B., Nusskern D., Rusch D.B.,
RA   Salzberg S., Shao W., Shue B., Sun J., Wang Z., Wang A., Wang X., Wang J.,
RA   Wei M., Wides R., Xiao C., Yan C., Yao A., Ye J., Zhan M., Zhang W.,
RA   Zhang H., Zhao Q., Zheng L., Zhong F., Zhong W., Zhu S., Zhao S.,
RA   Gilbert D., Baumhueter S., Spier G., Carter C., Cravchik A., Woodage T.,
RA   Ali F., An H., Awe A., Baldwin D., Baden H., Barnstead M., Barrow I.,
RA   Beeson K., Busam D., Carver A., Center A., Cheng M.L., Curry L.,
RA   Danaher S., Davenport L., Desilets R., Dietz S., Dodson K., Doup L.,
RA   Ferriera S., Garg N., Gluecksmann A., Hart B., Haynes J., Haynes C.,
RA   Heiner C., Hladun S., Hostin D., Houck J., Howland T., Ibegwam C.,
RA   Johnson J., Kalush F., Kline L., Koduru S., Love A., Mann F., May D.,
RA   McCawley S., McIntosh T., McMullen I., Moy M., Moy L., Murphy B.,
RA   Nelson K., Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N., Tse S.,
RA   Vech C., Wang G., Wetter J., Williams S., Williams M., Windsor S.,
RA   Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F., Guigo R.,
RA   Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A., Mi H., Lazareva B.,
RA   Hatton T., Narechania A., Diemer K., Muruganujan A., Guo N., Sato S.,
RA   Bafna V., Istrail S., Lippert R., Schwartz R., Walenz B., Yooseph S.,
RA   Allen D., Basu A., Baxendale J., Blick L., Caminha M., Carnes-Stine J.,
RA   Caulk P., Chiang Y.H., Coyne M., Dahlke C., Mays A., Dombroski M.,
RA   Donnelly M., Ely D., Esparham S., Fosler C., Gire H., Glanowski S.,
RA   Glasser K., Glodek A., Gorokhov M., Graham K., Gropman B., Harris M.,
RA   Heil J., Henderson S., Hoover J., Jennings D., Jordan C., Jordan J.,
RA   Kasha J., Kagan L., Kraft C., Levitsky A., Lewis M., Liu X., Lopez J.,
RA   Ma D., Majoros W., McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N.,
RA   Nodell M., Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAX03907.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CH471081; EAX03905.1; -; Genomic_DNA.
DR   EMBL; CH471081; EAX03907.1; -; Genomic_DNA.
DR   RefSeq; NP_000380.1; NM_000389.4.
DR   RefSeq; NP_001207706.1; NM_001220777.1.
DR   RefSeq; NP_001207707.1; NM_001220778.1.
DR   RefSeq; NP_510867.1; NM_078467.2.
DR   Antibodypedia; 3757; 2326 antibodies.
DR   GeneID; 1026; -.
DR   KEGG; hsa:1026; -.
DR   CTD; 1026; -.
DR   EuPathDB; HostDB:ENSG00000124762.13; -.
DR   eggNOG; KOG4743; Eukaryota.
DR   eggNOG; ENOG410XXN5; LUCA.
DR   HOGENOM; CLU_077692_1_1_1; -.
DR   KO; K06625; -.
DR   OMA; LEGNFAW; -.
DR   ChiTaRS; CDKN1A; human.
DR   GenomeRNAi; 1026; -.
DR   Bgee; ENSG00000124762; Expressed in left coronary artery and 228 other tissues.
DR   GO; GO:0000307; C:cyclin-dependent protein kinase holoenzyme complex; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0030332; F:cyclin binding; IEA:Ensembl.
DR   GO; GO:0004861; F:cyclin-dependent protein serine/threonine kinase inhibitor activity; IEA:Ensembl.
DR   GO; GO:0016301; F:kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0034198; P:cellular response to amino acid starvation; IEA:Ensembl.
DR   GO; GO:0071480; P:cellular response to gamma radiation; IEA:Ensembl.
DR   GO; GO:0034605; P:cellular response to heat; IEA:Ensembl.
DR   GO; GO:0071493; P:cellular response to UV-B; IEA:Ensembl.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0060574; P:intestinal epithelial cell maturation; IEA:Ensembl.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0071850; P:mitotic cell cycle arrest; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:1905179; P:negative regulation of cardiac muscle tissue regeneration; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; IEA:Ensembl.
DR   GO; GO:0043068; P:positive regulation of programmed cell death; IEA:Ensembl.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl.
DR   GO; GO:2000278; P:regulation of DNA biosynthetic process; IEA:Ensembl.
DR   GO; GO:0090399; P:replicative senescence; IEA:Ensembl.
DR   GO; GO:0046685; P:response to arsenic-containing substance; IEA:Ensembl.
DR   GO; GO:0051412; P:response to corticosterone; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0055093; P:response to hyperoxia; IEA:Ensembl.
DR   GO; GO:0010243; P:response to organonitrogen compound; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0010165; P:response to X-ray; IEA:Ensembl.
DR   GO; GO:0042246; P:tissue regeneration; IEA:Ensembl.
DR   InterPro; IPR003175; CDI.
DR   InterPro; IPR029841; CDKN1A.
DR   PANTHER; PTHR46778:SF1; PTHR46778:SF1; 1.
DR   Pfam; PF02234; CDI; 1.
PE   4: Predicted;
KW   Kinase {ECO:0000313|EMBL:EAX03907.1};
KW   Transferase {ECO:0000313|EMBL:EAX03907.1}.
FT   REGION          76..164
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ   SEQUENCE   164 AA;  18119 MW;  98D1E7C519ADFCA9 CRC64;
     MSEPAGDVRQ NPCGSKACRR LFGPVDSEQL SRDCDALMAG CIQEARERWN FDFVTETPLE
     GDFAWERVRG LGLPKLYLPT GPRRGRDELG GGRRPGTSPA LLQGTAEEDH VDLSLSCTLV
     PRSGEQAEGS PGGPGDSQGR KRRQTSMTDF YHSKRRLIFS KRKP
//
ID   CDN1A_HUMAN             Reviewed;         164 AA.
AC   P38936; Q14010; Q6FI05; Q9BUT4;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   22-APR-2020, entry version 225.
DE   RecName: Full=Cyclin-dependent kinase inhibitor 1;
DE   AltName: Full=CDK-interacting protein 1;
DE   AltName: Full=Melanoma differentiation-associated protein 6;
DE            Short=MDA-6;
DE   AltName: Full=p21;
GN   Name=CDKN1A; Synonyms=CAP20, CDKN1, CIP1, MDA6, PIC1, SDI1, WAF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND INDUCTION.
RX   PubMed=8242751; DOI=10.1016/0092-8674(93)90499-g;
RA   Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J.;
RT   "The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-
RT   dependent kinases.";
RL   Cell 75:805-816(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND INDUCTION.
RX   PubMed=8242752; DOI=10.1016/0092-8674(93)90500-p;
RA   El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R.,
RA   Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B.;
RT   "WAF1, a potential mediator of p53 tumor suppression.";
RL   Cell 75:817-825(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8259214; DOI=10.1038/366701a0;
RA   Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., Beach D.;
RT   "p21 is a universal inhibitor of cyclin kinases.";
RL   Nature 366:701-704(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Jiang H., Fisher P.B.;
RT   "Use of a sensitive and efficient subtraction hybridization protocol for
RT   the identification of genes differentially regulated during the induction
RT   of differentiation in human melanoma cells.";
RL   Mol. Cell. Differ. 1:285-299(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7753561;
RA   Jiang H., Lin J., Su Z.Z., Herlyn M., Kerbel R.S., Weissman B.E.,
RA   Welch D.R., Fisher P.B.;
RT   "The melanoma differentiation-associated gene mda-6, which encodes the
RT   cyclin-dependent kinase inhibitor p21, is differentially expressed during
RT   growth, differentiation and progression in human melanoma cells.";
RL   Oncogene 10:1855-1864(1995).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8125163; DOI=10.1006/excr.1994.1063;
RA   Noda A., Ning Y., Venable S.F., Pereira-Smith O.M., Smith J.R.;
RT   "Cloning of senescent cell-derived inhibitors of DNA synthesis using an
RT   expression screen.";
RL   Exp. Cell Res. 211:90-98(1994).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ARG-31.
RX   PubMed=7655464; DOI=10.1093/hmg/4.6.1089;
RA   Mousses S., Oezcelik H., Lee P.D., Malkin D., Bull S.B., Andrulis I.L.;
RT   "Two variants of the CIP1/WAF1 gene occur together and are associated with
RT   human cancer.";
RL   Hum. Mol. Genet. 4:1089-1092(1995).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ARG-31.
RG   NIEHS SNPs program;
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y.,
RA   Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A.,
RA   Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y.,
RA   Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T.,
RA   Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y.,
RA   Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S.,
RA   Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in vitro-
RT   expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ARG-31.
RC   TISSUE=Eye, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [15]
RP   PROTEIN SEQUENCE OF 2-16, ACETYLATION AT SER-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=15574338; DOI=10.1016/j.molcel.2004.11.011;
RA   Chen X., Chi Y., Bloecher A., Aebersold R., Clurman B.E., Roberts J.M.;
RT   "N-acetylation and ubiquitin-independent proteasomal degradation of
RT   p21(Cip1).";
RL   Mol. Cell 16:839-847(2004).
RN   [16]
RP   PROTEIN SEQUENCE OF 136-148, PHOSPHORYLATION AT THR-145; SER-146 AND
RP   SER-160, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=10753973; DOI=10.1074/jbc.275.15.11529;
RA   Scott M.T., Morrice N., Ball K.L.;
RT   "Reversible phosphorylation at the C-terminal regulatory domain of
RT   p21(Waf1/Cip1) modulates proliferating cell nuclear antigen binding.";
RL   J. Biol. Chem. 275:11529-11537(2000).
RN   [17]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CDK4 AND CCND1 IN THE
RP   CYCLIN D-CDK4-CDKN1A COMPLEX.
RX   PubMed=9106657; DOI=10.1101/gad.11.7.847;
RA   LaBaer J., Garrett M.D., Stevenson L.F., Slingerland J.M., Sandhu C.,
RA   Chou H.S., Fattaey A., Harlow E.;
RT   "New functional activities for the p21 family of CDK inhibitors.";
RL   Genes Dev. 11:847-862(1997).
RN   [18]
RP   INTERACTION WITH PSMA3.
RX   PubMed=11350925; DOI=10.1093/emboj/20.10.2367;
RA   Touitou R., Richardson J., Bose S., Nakanishi M., Rivett J., Allday M.J.;
RT   "A degradation signal located in the C-terminus of p21WAF1/CIP1 is a
RT   binding site for the C8 alpha-subunit of the 20S proteasome.";
RL   EMBO J. 20:2367-2375(2001).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH PCNA.
RX   PubMed=11595739; DOI=10.1074/jbc.m106990200;
RA   Ducoux M., Urbach S., Baldacci G., Huebscher U., Koundrioukoff S.,
RA   Christensen J., Hughes P.;
RT   "Mediation of proliferating cell nuclear antigen (PCNA)-dependent DNA
RT   replication through a conserved p21(Cip1)-like PCNA-binding motif present
RT   in the third subunit of human DNA polymerase delta.";
RL   J. Biol. Chem. 276:49258-49266(2001).
RN   [20]
RP   PHOSPHORYLATION AT THR-145, MUTAGENESIS OF THR-145 AND SER-146, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=11463845; DOI=10.1128/mcb.21.16.5644-5657.2001;
RA   Roessig L., Jadidi A.S., Urbich C., Badorff C., Zeiher A.M., Dimmeler S.;
RT   "Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and
RT   proliferation of endothelial cells.";
RL   Mol. Cell. Biol. 21:5644-5657(2001).
RN   [21]
RP   PHOSPHORYLATION AT THR-145 BY PIM1, SUBCELLULAR LOCATION, AND INTERACTION
RP   WITH PIM1.
RX   PubMed=12431783; DOI=10.1016/s0167-4889(02)00347-6;
RA   Wang Z., Bhattacharya N., Mixter P.F., Wei W., Sedivy J., Magnuson N.S.;
RT   "Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1
RT   kinase.";
RL   Biochim. Biophys. Acta 1593:45-55(2002).
RN   [22]
RP   UBIQUITINATION AT SER-2.
RX   PubMed=15226418; DOI=10.1128/mcb.24.14.6140-6150.2004;
RA   Coulombe P., Rodier G., Bonneil E., Thibault P., Meloche S.;
RT   "N-Terminal ubiquitination of extracellular signal-regulated kinase 3 and
RT   p21 directs their degradation by the proteasome.";
RL   Mol. Cell. Biol. 24:6140-6150(2004).
RN   [23]
RP   PHOSPHORYLATION AT THR-145.
RX   PubMed=16982699; DOI=10.1128/mcb.00201-06;
RA   Heron-Milhavet L., Franckhauser C., Rana V., Berthenet C., Fisher D.,
RA   Hemmings B.A., Fernandez A., Lamb N.J.;
RT   "Only Akt1 is required for proliferation, while Akt2 promotes cell cycle
RT   exit through p21 binding.";
RL   Mol. Cell. Biol. 26:8267-8280(2006).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-130, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [25]
RP   UBIQUITINATION, DOMAIN PIP-BOX K+4 MOTIF, INTERACTION WITH PCNA,
RP   MUTAGENESIS OF SER-114 AND 144-GLN--PHE-150, AND PHOSPHORYLATION AT
RP   SER-114.
RX   PubMed=18794347; DOI=10.1101/gad.1676108;
RA   Abbas T., Sivaprasad U., Terai K., Amador V., Pagano M., Dutta A.;
RT   "PCNA-dependent regulation of p21 ubiquitylation and degradation via the
RT   CRL4Cdt2 ubiquitin ligase complex.";
RL   Genes Dev. 22:2496-2506(2008).
RN   [26]
RP   UBIQUITINATION.
RX   PubMed=18794348; DOI=10.1101/gad.1703708;
RA   Kim Y., Starostina N.G., Kipreos E.T.;
RT   "The CRL4Cdt2 ubiquitin ligase targets the degradation of p21Cip1 to
RT   control replication licensing.";
RL   Genes Dev. 22:2507-2519(2008).
RN   [27]
RP   UBIQUITINATION, DOMAIN PIP-BOX K+4 MOTIF, MUTAGENESIS OF 147-MET--TYR-151
RP   AND 154-LYS--ARG-156, AND INTERACTION WITH PCNA.
RX   PubMed=18703516; DOI=10.1074/jbc.m806045200;
RA   Nishitani H., Shiomi Y., Iida H., Michishita M., Takami T., Tsurimoto T.;
RT   "CDK inhibitor p21 is degraded by a proliferating cell nuclear antigen-
RT   coupled Cul4-DDB1Cdt2 pathway during S phase and after UV irradiation.";
RL   J. Biol. Chem. 283:29045-29052(2008).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-130, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [29]
RP   REVIEW ON DNA REPAIR, AND INTERACTION WITH CDK2.
RX   PubMed=19445729; DOI=10.1186/1747-1028-4-9;
RA   Satyanarayana A., Kaldis P.;
RT   "A dual role of Cdk2 in DNA damage response.";
RL   Cell Div. 4:9-9(2009).
RN   [30]
RP   UBIQUITINATION, AND INTERACTION WITH MKRN1.
RX   PubMed=19536131; DOI=10.1038/emboj.2009.164;
RA   Lee E.-W., Lee M.-S., Camus S., Ghim J., Yang M.-R., Oh W., Ha N.-C.,
RA   Lane D.P., Song J.;
RT   "Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell
RT   cycle arrest and apoptosis.";
RL   EMBO J. 28:2100-2113(2009).
RN   [31]
RP   UBIQUITINATION.
RX   PubMed=19332548; DOI=10.1074/jbc.m808810200;
RA   Stuart S.A., Wang J.Y.;
RT   "Ionizing radiation induces ATM-independent degradation of p21Cip1 in
RT   transformed cells.";
RL   J. Biol. Chem. 284:15061-15070(2009).
RN   [32]
RP   PHOSPHORYLATION AT THR-145 BY PIM2.
RX   PubMed=20307683; DOI=10.1016/j.biocel.2010.03.012;
RA   Wang Z., Zhang Y., Gu J.J., Davitt C., Reeves R., Magnuson N.S.;
RT   "Pim-2 phosphorylation of p21(Cip1/WAF1) enhances its stability and
RT   inhibits cell proliferation in HCT116 cells.";
RL   Int. J. Biochem. Cell Biol. 42:1030-1038(2010).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [34]
RP   FUNCTION, INTERACTION WITH TRIM39 AND DTL, SUBCELLULAR LOCATION,
RP   UBIQUITINATION, PROTEASOMAL DEGRADATION, AND MUTAGENESIS OF LYS-154.
RX   PubMed=23213251; DOI=10.1073/pnas.1214156110;
RA   Zhang L., Mei Y., Fu N.Y., Guan L., Xie W., Liu H.H., Yu C.D., Yin Z.,
RA   Yu V.C., You H.;
RT   "TRIM39 regulates cell cycle progression and DNA damage responses via
RT   stabilizing p21.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:20937-20942(2012).
RN   [35]
RP   UBIQUITINATION BY RNF114.
RX   PubMed=23645206; DOI=10.1038/cdd.2013.33;
RA   Han J., Kim Y.L., Lee K.W., Her N.G., Ha T.K., Yoon S., Jeong S.I.,
RA   Lee J.H., Kang M.J., Lee M.G., Ryu B.K., Baik J.H., Chi S.G.;
RT   "ZNF313 is a novel cell cycle activator with an E3 ligase activity
RT   inhibiting cellular senescence by destabilizing p21(WAF1.).";
RL   Cell Death Differ. 20:1055-1067(2013).
RN   [36]
RP   FUNCTION, INTERACTION WITH STK11 AND NUAK1, PHOSPHORYLATION AT THR-80 AND
RP   SER-146, AND MUTAGENESIS OF THR-80 AND SER-146.
RX   PubMed=25329316; DOI=10.1371/journal.pgen.1004721;
RA   Esteve-Puig R., Gil R., Gonzalez-Sanchez E., Bech-Serra J.J., Grueso J.,
RA   Hernandez-Losa J., Moline T., Canals F., Ferrer B., Cortes J., Bastian B.,
RA   Cajal S.R.Y., Martin-Caballero J., Flores J.M., Vivancos A.,
RA   Garcia-Patos V., Recio J.A.;
RT   "A mouse model uncovers LKB1 as an UVB-induced DNA damage sensor mediating
RT   CDKN1A (p21WAF1/CIP1) degradation.";
RL   PLoS Genet. 10:E1004721-E1004721(2014).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 139-160 IN COMPLEX WITH PCNA.
RX   PubMed=8861913; DOI=10.1016/s0092-8674(00)81347-1;
RA   Gulbis J.M., Kelman Z., Hurwitz J., O'Donnell M., Kuriyan J.;
RT   "Structure of the C-terminal region of p21(WAF1/CIP1) complexed with human
RT   PCNA.";
RL   Cell 87:297-306(1996).
CC   -!- FUNCTION: May be involved in p53/TP53 mediated inhibition of cellular
CC       proliferation in response to DNA damage. Binds to and inhibits cyclin-
CC       dependent kinase activity, preventing phosphorylation of critical
CC       cyclin-dependent kinase substrates and blocking cell cycle progression.
CC       Functions in the nuclear localization and assembly of cyclin D-CDK4
CC       complex and promotes its kinase activity towards RB1. At higher
CC       stoichiometric ratios, inhibits the kinase activity of the cyclin D-
CC       CDK4 complex. Inhibits DNA synthesis by DNA polymerase delta by
CC       competing with POLD3 for PCNA binding (PubMed:11595739). Plays an
CC       important role in controlling cell cycle progression and DNA damage-
CC       induced G2 arrest (PubMed:9106657). {ECO:0000269|PubMed:11595739,
CC       ECO:0000269|PubMed:8242751, ECO:0000269|PubMed:9106657}.
CC   -!- SUBUNIT: Interacts with HDAC1; the interaction is prevented by
CC       competitive binding of C10orf90/FATS to HDAC1 facilitating acetylation
CC       and protein stabilization of CDKN1A/p21 (By similarity). Interacts with
CC       MKRN1 (PubMed:19536131). Interacts with PSMA3 (PubMed:11350925).
CC       Interacts with PCNA (PubMed:11595739, PubMed:18794347, PubMed:18703516,
CC       PubMed:8861913). Component of the ternary complex, cyclin D-CDK4-
CC       CDKN1A. Interacts (via its N-terminal domain) with CDK4; the
CC       interaction promotes the assembly of the cyclin D-CDK4 complex, its
CC       nuclear translocation and promotes the cyclin D-dependent enzyme
CC       activity of CDK4 (PubMed:9106657). Binding to CDK2 leads to CDK2/cyclin
CC       E inactivation at the G1-S phase DNA damage checkpoint, thereby
CC       arresting cells at the G1-S transition during DNA repair
CC       (PubMed:19445729). Interacts with PIM1 (PubMed:12431783). Interacts
CC       with STK11 and NUAK1 (PubMed:25329316). Interacts wih DTL
CC       (PubMed:23213251). Interacts with isoform 1 and isoform 2 of TRIM39
CC       (PubMed:23213251). {ECO:0000250|UniProtKB:P39689,
CC       ECO:0000269|PubMed:11350925, ECO:0000269|PubMed:11595739,
CC       ECO:0000269|PubMed:12431783, ECO:0000269|PubMed:18703516,
CC       ECO:0000269|PubMed:18794347, ECO:0000269|PubMed:19445729,
CC       ECO:0000269|PubMed:19536131, ECO:0000269|PubMed:23213251,
CC       ECO:0000269|PubMed:25329316, ECO:0000269|PubMed:8861913,
CC       ECO:0000269|PubMed:9106657}.
CC   -!- INTERACTION:
CC       P38936; PRO_0000037566 [P27958]; Xeno; NbExp=3; IntAct=EBI-375077, EBI-6377335;
CC       P38936; P78396: CCNA1; NbExp=7; IntAct=EBI-375077, EBI-375065;
CC       P38936; P20248: CCNA2; NbExp=5; IntAct=EBI-375077, EBI-457097;
CC       P38936; P14635: CCNB1; NbExp=2; IntAct=EBI-375077, EBI-495332;
CC       P38936; P24385: CCND1; NbExp=18; IntAct=EBI-375077, EBI-375001;
CC       P38936; P30279: CCND2; NbExp=17; IntAct=EBI-375077, EBI-748789;
CC       P38936; P30281: CCND3; NbExp=24; IntAct=EBI-375077, EBI-375013;
CC       P38936; P24864: CCNE1; NbExp=9; IntAct=EBI-375077, EBI-519526;
CC       P38936; O96020: CCNE2; NbExp=6; IntAct=EBI-375077, EBI-375033;
CC       P38936; O75419: CDC45; NbExp=2; IntAct=EBI-375077, EBI-374969;
CC       P38936; Q99741: CDC6; NbExp=2; IntAct=EBI-375077, EBI-374862;
CC       P38936; P06493: CDK1; NbExp=5; IntAct=EBI-375077, EBI-444308;
CC       P38936; O94921: CDK14; NbExp=8; IntAct=EBI-375077, EBI-1043945;
CC       P38936; P24941: CDK2; NbExp=28; IntAct=EBI-375077, EBI-375096;
CC       P38936; Q00526: CDK3; NbExp=6; IntAct=EBI-375077, EBI-1245761;
CC       P38936; P11802: CDK4; NbExp=7; IntAct=EBI-375077, EBI-295644;
CC       P38936; Q00535: CDK5; NbExp=5; IntAct=EBI-375077, EBI-1041567;
CC       P38936; Q00534: CDK6; NbExp=2; IntAct=EBI-375077, EBI-295663;
CC       P38936; Q9BVV2: FNDC11; NbExp=3; IntAct=EBI-375077, EBI-744935;
CC       P38936; Q08379: GOLGA2; NbExp=3; IntAct=EBI-375077, EBI-618309;
CC       P38936; Q96ED9-2: HOOK2; NbExp=3; IntAct=EBI-375077, EBI-10961706;
CC       P38936; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-375077, EBI-747204;
CC       P38936; Q0VD86: INCA1; NbExp=3; IntAct=EBI-375077, EBI-6509505;
CC       P38936; Q9BVG8-5: KIFC3; NbExp=3; IntAct=EBI-375077, EBI-14069005;
CC       P38936; Q15323: KRT31; NbExp=6; IntAct=EBI-375077, EBI-948001;
CC       P38936; Q9BYR8: KRTAP3-1; NbExp=3; IntAct=EBI-375077, EBI-9996449;
CC       P38936; Q9P2M1: LRP2BP; NbExp=3; IntAct=EBI-375077, EBI-18273118;
CC       P38936; Q9BRK4: LZTS2; NbExp=3; IntAct=EBI-375077, EBI-741037;
CC       P38936; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-375077, EBI-16439278;
CC       P38936; Q9UHC7: MKRN1; NbExp=5; IntAct=EBI-375077, EBI-373524;
CC       P38936; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-375077, EBI-11522433;
CC       P38936; Q9BQ15: NABP2; NbExp=7; IntAct=EBI-375077, EBI-2120336;
CC       P38936; P12004: PCNA; NbExp=37; IntAct=EBI-375077, EBI-358311;
CC       P38936; Q6FI35: PCNA; NbExp=2; IntAct=EBI-375077, EBI-8469539;
CC       P38936; P31321: PRKAR1B; NbExp=3; IntAct=EBI-375077, EBI-2805516;
CC       P38936; Q04864-2: REL; NbExp=3; IntAct=EBI-375077, EBI-10829018;
CC       P38936; Q9UQR0-1: SCML2; NbExp=3; IntAct=EBI-375077, EBI-16087037;
CC       P38936; Q6ZSJ9: SHISA6; NbExp=3; IntAct=EBI-375077, EBI-12037847;
CC       P38936; Q96FS4: SIPA1; NbExp=2; IntAct=EBI-375077, EBI-1054981;
CC       P38936; P63208: SKP1; NbExp=3; IntAct=EBI-375077, EBI-307486;
CC       P38936; Q13309: SKP2; NbExp=3; IntAct=EBI-375077, EBI-456291;
CC       P38936; P51692: STAT5B; NbExp=3; IntAct=EBI-375077, EBI-1186119;
CC       P38936; P15884: TCF4; NbExp=3; IntAct=EBI-375077, EBI-533224;
CC       P38936; Q8IYF3: TEX11; NbExp=4; IntAct=EBI-375077, EBI-742397;
CC       P38936; Q9UBB9: TFIP11; NbExp=3; IntAct=EBI-375077, EBI-1105213;
CC       P38936; P04637: TP53; NbExp=3; IntAct=EBI-375077, EBI-366083;
CC       P38936; Q13077: TRAF1; NbExp=3; IntAct=EBI-375077, EBI-359224;
CC       P38936; Q9BYV2: TRIM54; NbExp=6; IntAct=EBI-375077, EBI-2130429;
CC       P38936; Q8N6Y0: USHBP1; NbExp=3; IntAct=EBI-375077, EBI-739895;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:11463845}. Nucleus
CC       {ECO:0000269|PubMed:11463845, ECO:0000269|PubMed:23213251}.
CC   -!- TISSUE SPECIFICITY: Expressed in all adult tissues, with 5-fold lower
CC       levels observed in the brain.
CC   -!- INDUCTION: Activated by p53/TP53, mezerein (antileukemic compound) and
CC       IFNB1. Repressed by HDAC1. {ECO:0000269|PubMed:8242751,
CC       ECO:0000269|PubMed:8242752}.
CC   -!- DOMAIN: The PIP-box K+4 motif mediates both the interaction with PCNA
CC       and the recruitment of the DCX(DTL) complex: while the PIP-box
CC       interacts with PCNA, the presence of the K+4 submotif, recruits the
CC       DCX(DTL) complex, leading to its ubiquitination.
CC   -!- DOMAIN: The C-terminal is required for nuclear localization of the
CC       cyclin D-CDK4 complex.
CC   -!- PTM: Phosphorylation of Thr-145 by Akt or of Ser-146 by PKC impairs
CC       binding to PCNA. Phosphorylation at Ser-114 by GSK3-beta enhances
CC       ubiquitination by the DCX(DTL) complex. Phosphorylation of Thr-145 by
CC       PIM2 enhances CDKN1A stability and inhibits cell proliferation.
CC       Phosphorylation of Thr-145 by PIM1 results in the relocation of CDKN1A
CC       to the cytoplasm and enhanced CDKN1A protein stability. UV radiation-
CC       induced phosphorylation at Thr-80 by LKB1 and at Ser-146 by NUAK1 leads
CC       to its degradation. {ECO:0000269|PubMed:10753973,
CC       ECO:0000269|PubMed:11463845, ECO:0000269|PubMed:12431783,
CC       ECO:0000269|PubMed:16982699, ECO:0000269|PubMed:18794347,
CC       ECO:0000269|PubMed:20307683, ECO:0000269|PubMed:25329316}.
CC   -!- PTM: Ubiquitinated by MKRN1; leading to polyubiquitination and 26S
CC       proteasome-dependent degradation. Ubiquitinated by the DCX(DTL)
CC       complex, also named CRL4(CDT2) complex, leading to its degradation
CC       during S phase or following UV irradiation. Ubiquitination by the
CC       DCX(DTL) complex is essential to control replication licensing and is
CC       PCNA-dependent: interacts with PCNA via its PIP-box, while the presence
CC       of the containing the 'K+4' motif in the PIP box, recruit the DCX(DTL)
CC       complex, leading to its degradation. Ubiquitination at Ser-2 leads to
CC       degradation by the proteasome pathway. Ubiquitinated by RNF114; leading
CC       to proteasomal degradation. {ECO:0000269|PubMed:15226418,
CC       ECO:0000269|PubMed:23213251}.
CC   -!- PTM: Acetylation leads to protein stability. Acetylated in vitro on
CC       Lys-141, Lys-154, Lys-161 and Lys-163. Deacetylation by HDAC1 is
CC       prevented by competitive binding of C10orf90/FATS to HDAC1 (By
CC       similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the CDI family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB59559.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAB59560.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CDKN1AID139.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cdkn1a/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L25610; AAA16109.1; -; mRNA.
DR   EMBL; S67388; AAB29246.1; -; mRNA.
DR   EMBL; U09579; AAA85641.1; -; mRNA.
DR   EMBL; U03106; AAC04313.1; -; mRNA.
DR   EMBL; L26165; AAA19811.1; -; mRNA.
DR   EMBL; L47232; AAB59559.1; ALT_INIT; mRNA.
DR   EMBL; L47233; AAB59560.1; ALT_INIT; mRNA.
DR   EMBL; AF497972; AAM11787.1; -; Genomic_DNA.
DR   EMBL; BT006719; AAP35365.1; -; mRNA.
DR   EMBL; AB451290; BAG70104.1; -; mRNA.
DR   EMBL; AB451422; BAG70236.1; -; mRNA.
DR   EMBL; CR536533; CAG38770.1; -; mRNA.
DR   EMBL; Z85996; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471081; EAX03904.1; -; Genomic_DNA.
DR   EMBL; BC000275; AAH00275.1; -; mRNA.
DR   EMBL; BC000312; AAH00312.1; -; mRNA.
DR   EMBL; BC001935; AAH01935.1; -; mRNA.
DR   EMBL; BC013967; AAH13967.1; -; mRNA.
DR   CCDS; CCDS4824.1; -.
DR   PIR; I54380; I54380.
DR   PIR; I68674; I68674.
DR   RefSeq; NP_000380.1; NM_000389.4.
DR   RefSeq; NP_001207706.1; NM_001220777.1.
DR   RefSeq; NP_001207707.1; NM_001220778.1.
DR   RefSeq; NP_001278478.1; NM_001291549.1.
DR   RefSeq; NP_510867.1; NM_078467.2.
DR   PDB; 1AXC; X-ray; 2.60 A; B/D/F=139-160.
DR   PDB; 2ZVV; X-ray; 2.00 A; X/Y=139-160.
DR   PDB; 2ZVW; X-ray; 2.50 A; I/J/K/L/M/N/O/P=139-160.
DR   PDB; 4RJF; X-ray; 2.01 A; B/D/F=139-160.
DR   PDB; 5E0U; X-ray; 1.93 A; D/E/F=139-160.
DR   PDB; 6CBI; X-ray; 2.75 A; H/I/J/K=139-152.
DR   PDB; 6CEJ; NMR; -; A=139-152.
DR   PDB; 6CIV; NMR; -; C=139-152.
DR   PDB; 6CIX; NMR; -; B=139-152.
DR   PDB; 6P8H; X-ray; 3.19 A; C=9-85.
DR   PDBsum; 1AXC; -.
DR   PDBsum; 2ZVV; -.
DR   PDBsum; 2ZVW; -.
DR   PDBsum; 4RJF; -.
DR   PDBsum; 5E0U; -.
DR   PDBsum; 6CBI; -.
DR   PDBsum; 6CEJ; -.
DR   PDBsum; 6CIV; -.
DR   PDBsum; 6CIX; -.
DR   PDBsum; 6P8H; -.
DR   SMR; P38936; -.
DR   BioGrid; 107460; 301.
DR   CORUM; P38936; -.
DR   DIP; DIP-246N; -.
DR   IntAct; P38936; 194.
DR   MINT; P38936; -.
DR   STRING; 9606.ENSP00000384849; -.
DR   BindingDB; P38936; -.
DR   ChEMBL; CHEMBL5021; -.
DR   DrugBank; DB01169; Arsenic trioxide.
DR   MoonDB; P38936; Predicted.
DR   iPTMnet; P38936; -.
DR   PhosphoSitePlus; P38936; -.
DR   BioMuta; CDKN1A; -.
DR   DMDM; 729143; -.
DR   SWISS-2DPAGE; P38936; -.
DR   EPD; P38936; -.
DR   jPOST; P38936; -.
DR   MassIVE; P38936; -.
DR   PaxDb; P38936; -.
DR   PeptideAtlas; P38936; -.
DR   PRIDE; P38936; -.
DR   ProteomicsDB; 55307; -.
DR   Antibodypedia; 3757; 2326 antibodies.
DR   DNASU; 1026; -.
DR   Ensembl; ENST00000244741; ENSP00000244741; ENSG00000124762.
DR   Ensembl; ENST00000373711; ENSP00000362815; ENSG00000124762.
DR   Ensembl; ENST00000405375; ENSP00000384849; ENSG00000124762.
DR   Ensembl; ENST00000448526; ENSP00000409259; ENSG00000124762.
DR   Ensembl; ENST00000615513; ENSP00000482768; ENSG00000124762.
DR   GeneID; 1026; -.
DR   KEGG; hsa:1026; -.
DR   UCSC; uc003omm.5; human.
DR   CTD; 1026; -.
DR   DisGeNET; 1026; -.
DR   GeneCards; CDKN1A; -.
DR   HGNC; HGNC:1784; CDKN1A.
DR   HPA; ENSG00000124762; Low tissue specificity.
DR   MalaCards; CDKN1A; -.
DR   MIM; 116899; gene.
DR   neXtProt; NX_P38936; -.
DR   OpenTargets; ENSG00000124762; -.
DR   Orphanet; 652; Multiple endocrine neoplasia type 1.
DR   PharmGKB; PA104; -.
DR   eggNOG; KOG4743; Eukaryota.
DR   eggNOG; ENOG410XXN5; LUCA.
DR   GeneTree; ENSGT00940000159918; -.
DR   HOGENOM; CLU_077692_1_1_1; -.
DR   InParanoid; P38936; -.
DR   KO; K06625; -.
DR   OMA; LEGNFAW; -.
DR   OrthoDB; 962484at2759; -.
DR   PhylomeDB; P38936; -.
DR   TreeFam; TF101038; -.
DR   Reactome; R-HSA-187577; SCF(Skp2)-mediated degradation of p27/p21.
DR   Reactome; R-HSA-198323; AKT phosphorylates targets in the cytosol.
DR   Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence.
DR   Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-6804116; TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest.
DR   Reactome; R-HSA-69202; Cyclin E associated events during G1/S transition.
DR   Reactome; R-HSA-69231; Cyclin D associated events in G1.
DR   Reactome; R-HSA-69563; p53-Dependent G1 DNA Damage Response.
DR   Reactome; R-HSA-69656; Cyclin A:Cdk2-associated events at S phase entry.
DR   Reactome; R-HSA-69895; Transcriptional activation of cell cycle inhibitor p21.
DR   Reactome; R-HSA-8852276; The role of GTSE1 in G2/M progression after G2 checkpoint.
DR   Reactome; R-HSA-8866911; TFAP2 (AP-2) family regulates transcription of cell cycle factors.
DR   Reactome; R-HSA-8878166; Transcriptional regulation by RUNX2.
DR   Reactome; R-HSA-8941855; RUNX3 regulates CDKN1A transcription.
DR   Reactome; R-HSA-9616222; Transcriptional regulation of granulopoiesis.
DR   Reactome; R-HSA-9617828; FOXO-mediated transcription of cell cycle genes.
DR   SIGNOR; P38936; -.
DR   ChiTaRS; CDKN1A; human.
DR   EvolutionaryTrace; P38936; -.
DR   GeneWiki; P21; -.
DR   GenomeRNAi; 1026; -.
DR   Pharos; P38936; Tbio.
DR   PRO; PR:P38936; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; P38936; protein.
DR   Bgee; ENSG00000124762; Expressed in left coronary artery and 228 other tissues.
DR   ExpressionAtlas; P38936; baseline and differential.
DR   Genevisible; P38936; HS.
DR   GO; GO:0000307; C:cyclin-dependent protein kinase holoenzyme complex; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:MGI.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0070557; C:PCNA-p21 complex; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0032991; C:protein-containing complex; IDA:MGI.
DR   GO; GO:0030332; F:cyclin binding; ISS:BHF-UCL.
DR   GO; GO:0019912; F:cyclin-dependent protein kinase activating kinase activity; IDA:UniProtKB.
DR   GO; GO:0004861; F:cyclin-dependent protein serine/threonine kinase inhibitor activity; TAS:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0019901; F:protein kinase binding; IPI:CAFA.
DR   GO; GO:0004860; F:protein kinase inhibitor activity; IMP:CAFA.
DR   GO; GO:0140311; F:protein sequestering activity; IMP:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IPI:CAFA.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0007050; P:cell cycle arrest; IDA:BHF-UCL.
DR   GO; GO:0034198; P:cellular response to amino acid starvation; IMP:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IMP:BHF-UCL.
DR   GO; GO:0031668; P:cellular response to extracellular stimulus; IMP:BHF-UCL.
DR   GO; GO:0071480; P:cellular response to gamma radiation; IEA:Ensembl.
DR   GO; GO:0034605; P:cellular response to heat; IEA:Ensembl.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; IMP:BHF-UCL.
DR   GO; GO:0071493; P:cellular response to UV-B; ISS:UniProtKB.
DR   GO; GO:0090398; P:cellular senescence; IMP:BHF-UCL.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; IDA:BHF-UCL.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IEA:Ensembl.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IDA:BHF-UCL.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IMP:BHF-UCL.
DR   GO; GO:0007507; P:heart development; ISS:BHF-UCL.
DR   GO; GO:0060574; P:intestinal epithelial cell maturation; IEA:Ensembl.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; TAS:ProtInc.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0071850; P:mitotic cell cycle arrest; ISS:BHF-UCL.
DR   GO; GO:0007095; P:mitotic G2 DNA damage checkpoint; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:1905179; P:negative regulation of cardiac muscle tissue regeneration; ISS:BHF-UCL.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:BHF-UCL.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:1904030; P:negative regulation of cyclin-dependent protein kinase activity; IMP:CAFA.
DR   GO; GO:2000279; P:negative regulation of DNA biosynthetic process; IMP:UniProtKB.
DR   GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IGI:MGI.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0042326; P:negative regulation of phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0032091; P:negative regulation of protein binding; IMP:UniProtKB.
DR   GO; GO:1904706; P:negative regulation of vascular smooth muscle cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; IEA:Ensembl.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IMP:BHF-UCL.
DR   GO; GO:0043068; P:positive regulation of programmed cell death; IEA:Ensembl.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IDA:MGI.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL.
DR   GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0050821; P:protein stabilization; TAS:Reactome.
DR   GO; GO:0007265; P:Ras protein signal transduction; IEP:BHF-UCL.
DR   GO; GO:1902806; P:regulation of cell cycle G1/S phase transition; IMP:UniProtKB.
DR   GO; GO:0000079; P:regulation of cyclin-dependent protein serine/threonine kinase activity; TAS:ProtInc.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; TAS:Reactome.
DR   GO; GO:0090399; P:replicative senescence; IEA:Ensembl.
DR   GO; GO:0046685; P:response to arsenic-containing substance; IEA:Ensembl.
DR   GO; GO:0051412; P:response to corticosterone; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0055093; P:response to hyperoxia; IEA:Ensembl.
DR   GO; GO:0010243; P:response to organonitrogen compound; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0010165; P:response to X-ray; IEA:Ensembl.
DR   GO; GO:0090400; P:stress-induced premature senescence; TAS:BHF-UCL.
DR   GO; GO:0042246; P:tissue regeneration; IEA:Ensembl.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   DisProt; DP00016; -.
DR   InterPro; IPR003175; CDI.
DR   InterPro; IPR029841; CDKN1A.
DR   PANTHER; PTHR46778:SF1; PTHR46778:SF1; 1.
DR   Pfam; PF02234; CDI; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cell cycle; Cytoplasm;
KW   Direct protein sequencing; Metal-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Protein kinase inhibitor; Reference proteome;
KW   Ubl conjugation; Zinc; Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:15574338"
FT   CHAIN           2..164
FT                   /note="Cyclin-dependent kinase inhibitor 1"
FT                   /id="PRO_0000190079"
FT   ZN_FING         13..41
FT                   /note="C4-type"
FT                   /evidence="ECO:0000255"
FT   REGION          17..24
FT                   /note="Required for binding cyclins"
FT   REGION          53..58
FT                   /note="Required for binding CDKs"
FT   REGION          152..164
FT                   /note="Interaction with TRIM39"
FT                   /evidence="ECO:0000269|PubMed:23213251"
FT   MOTIF           140..164
FT                   /note="PIP-box K+4 motif"
FT   MOTIF           141..156
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000269|PubMed:15574338"
FT   MOD_RES         80
FT                   /note="Phosphothreonine; by LKB1"
FT                   /evidence="ECO:0000269|PubMed:25329316"
FT   MOD_RES         114
FT                   /note="Phosphoserine; by GSK3-beta"
FT                   /evidence="ECO:0000269|PubMed:18794347"
FT   MOD_RES         130
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:16964243,
FT                   ECO:0000244|PubMed:18669648"
FT   MOD_RES         145
FT                   /note="Phosphothreonine; by PKA, PKB/AKT1, PIM1 and PIM2"
FT                   /evidence="ECO:0000269|PubMed:10753973,
FT                   ECO:0000269|PubMed:11463845, ECO:0000269|PubMed:12431783,
FT                   ECO:0000269|PubMed:16982699, ECO:0000269|PubMed:20307683"
FT   MOD_RES         146
FT                   /note="Phosphoserine; by PKC and NUAK1"
FT                   /evidence="ECO:0000269|PubMed:10753973,
FT                   ECO:0000269|PubMed:25329316"
FT   MOD_RES         160
FT                   /note="Phosphoserine; by PKC; in vitro"
FT                   /evidence="ECO:0000269|PubMed:10753973"
FT   CROSSLNK        2
FT                   /note="Glycyl serine ester (Ser-Gly) (interchain with G-
FT                   Cter in ubiquitin)"
FT                   /evidence="ECO:0000305|PubMed:15226418"
FT   VARIANT         4
FT                   /note="P -> L (in dbSNP:rs4986866)"
FT                   /id="VAR_048686"
FT   VARIANT         31
FT                   /note="S -> R (in dbSNP:rs1801270)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:7655464, ECO:0000269|Ref.8"
FT                   /id="VAR_011870"
FT   VARIANT         63
FT                   /note="F -> L (in dbSNP:rs4986867)"
FT                   /id="VAR_048687"
FT   MUTAGEN         80
FT                   /note="T->A: Abolishes UV radiation-induced phosphorylation
FT                   and subsequent degradation."
FT                   /evidence="ECO:0000269|PubMed:25329316"
FT   MUTAGEN         114
FT                   /note="S->E: Phosphomimetic mutant, increases
FT                   ubiquitination by the DCX(DTL) complex."
FT                   /evidence="ECO:0000269|PubMed:18794347"
FT   MUTAGEN         144..150
FT                   /note="QTSMTDF->ATSATDA: Abolishes interaction with PCNA
FT                   and subsequent degradation by the proteasome."
FT                   /evidence="ECO:0000269|PubMed:18794347"
FT   MUTAGEN         145
FT                   /note="T->A: Reduces phosphorylation by Akt; no change in
FT                   interaction with PCNA, CDK2 or CDK4; no change in
FT                   subcellular location."
FT                   /evidence="ECO:0000269|PubMed:11463845"
FT   MUTAGEN         145
FT                   /note="T->D: No interaction with PCNA; 59% inhibition of
FT                   CDK2 binding; modest inhibition of CDK4 binding; no change
FT                   in subcellular location."
FT                   /evidence="ECO:0000269|PubMed:11463845"
FT   MUTAGEN         146
FT                   /note="S->A: No change in interaction with PCNA. Abolishes
FT                   UV radiation-induced phosphorylation and subsequent
FT                   degradation."
FT                   /evidence="ECO:0000269|PubMed:11463845,
FT                   ECO:0000269|PubMed:25329316"
FT   MUTAGEN         146
FT                   /note="S->D: Reduces interaction with PCNA."
FT                   /evidence="ECO:0000269|PubMed:11463845"
FT   MUTAGEN         147..151
FT                   /note="MTDFY->ATDAAA: Abolishes interaction with PCNA and
FT                   subsequent degradation by the proteasome."
FT                   /evidence="ECO:0000269|PubMed:18703516"
FT   MUTAGEN         154..156
FT                   /note="KRR->AAA: Abolishes degradation by the proteasome
FT                   without affecting the interaction with PCNA."
FT                   /evidence="ECO:0000269|PubMed:18703516"
FT   MUTAGEN         154
FT                   /note="K->A: Loss of interaction with TRIM39."
FT                   /evidence="ECO:0000269|PubMed:23213251"
FT   HELIX           147..149
FT                   /evidence="ECO:0000244|PDB:5E0U"
FT   STRAND          153..158
FT                   /evidence="ECO:0000244|PDB:5E0U"
SQ   SEQUENCE   164 AA;  18119 MW;  98D1E7C519ADFCA9 CRC64;
     MSEPAGDVRQ NPCGSKACRR LFGPVDSEQL SRDCDALMAG CIQEARERWN FDFVTETPLE
     GDFAWERVRG LGLPKLYLPT GPRRGRDELG GGRRPGTSPA LLQGTAEEDH VDLSLSCTLV
     PRSGEQAEGS PGGPGDSQGR KRRQTSMTDF YHSKRRLIFS KRKP
//
ID   A0A024R9C1_HUMAN        Unreviewed;       636 AA.
AC   A0A024R9C1;
DT   09-JUL-2014, integrated into UniProtKB/TrEMBL.
DT   09-JUL-2014, sequence version 1.
DT   22-APR-2020, entry version 50.
DE   RecName: Full=Polyadenylate-binding protein {ECO:0000256|RuleBase:RU362004};
DE            Short=PABP {ECO:0000256|RuleBase:RU362004};
GN   Name=PABPC1 {ECO:0000313|EMBL:EAW91817.1};
GN   ORFNames=hCG_15683 {ECO:0000313|EMBL:EAW91817.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:EAW91817.1};
RN   [1] {ECO:0000313|EMBL:EAW91817.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D., Amanatides P.,
RA   Ballew R.M., Huson D.H., Wortman J.R., Zhang Q., Kodira C.D., Zheng X.H.,
RA   Chen L., Skupski M., Subramanian G., Thomas P.D., Zhang J.,
RA   Gabor Miklos G.L., Nelson C., Broder S., Clark A.G., Nadeau J.,
RA   McKusick V.A., Zinder N., Levine A.J., Roberts R.J., Simon M., Slayman C.,
RA   Hunkapiller M., Bolanos R., Delcher A., Dew I., Fasulo D., Flanigan M.,
RA   Florea L., Halpern A., Hannenhalli S., Kravitz S., Levy S., Mobarry C.,
RA   Reinert K., Remington K., Abu-Threideh J., Beasley E., Biddick K.,
RA   Bonazzi V., Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z., Guan P.,
RA   Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A., Lai Z., Lei Y.,
RA   Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V., Milshina N.,
RA   Moore H.M., Naik A.K., Narayan V.A., Neelam B., Nusskern D., Rusch D.B.,
RA   Salzberg S., Shao W., Shue B., Sun J., Wang Z., Wang A., Wang X., Wang J.,
RA   Wei M., Wides R., Xiao C., Yan C., Yao A., Ye J., Zhan M., Zhang W.,
RA   Zhang H., Zhao Q., Zheng L., Zhong F., Zhong W., Zhu S., Zhao S.,
RA   Gilbert D., Baumhueter S., Spier G., Carter C., Cravchik A., Woodage T.,
RA   Ali F., An H., Awe A., Baldwin D., Baden H., Barnstead M., Barrow I.,
RA   Beeson K., Busam D., Carver A., Center A., Cheng M.L., Curry L.,
RA   Danaher S., Davenport L., Desilets R., Dietz S., Dodson K., Doup L.,
RA   Ferriera S., Garg N., Gluecksmann A., Hart B., Haynes J., Haynes C.,
RA   Heiner C., Hladun S., Hostin D., Houck J., Howland T., Ibegwam C.,
RA   Johnson J., Kalush F., Kline L., Koduru S., Love A., Mann F., May D.,
RA   McCawley S., McIntosh T., McMullen I., Moy M., Moy L., Murphy B.,
RA   Nelson K., Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N., Tse S.,
RA   Vech C., Wang G., Wetter J., Williams S., Williams M., Windsor S.,
RA   Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F., Guigo R.,
RA   Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A., Mi H., Lazareva B.,
RA   Hatton T., Narechania A., Diemer K., Muruganujan A., Guo N., Sato S.,
RA   Bafna V., Istrail S., Lippert R., Schwartz R., Walenz B., Yooseph S.,
RA   Allen D., Basu A., Baxendale J., Blick L., Caminha M., Carnes-Stine J.,
RA   Caulk P., Chiang Y.H., Coyne M., Dahlke C., Mays A., Dombroski M.,
RA   Donnelly M., Ely D., Esparham S., Fosler C., Gire H., Glanowski S.,
RA   Glasser K., Glodek A., Gorokhov M., Graham K., Gropman B., Harris M.,
RA   Heil J., Henderson S., Hoover J., Jennings D., Jordan C., Jordan J.,
RA   Kasha J., Kagan L., Kraft C., Levitsky A., Lewis M., Liu X., Lopez J.,
RA   Ma D., Majoros W., McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N.,
RA   Nodell M., Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAW91817.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Binds the poly(A) tail of mRNA.
CC       {ECO:0000256|RuleBase:RU362004}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|RuleBase:RU362004}.
CC   -!- SIMILARITY: Belongs to the polyadenylate-binding protein type-1 family.
CC       {ECO:0000256|RuleBase:RU362004}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CH471060; EAW91815.1; -; Genomic_DNA.
DR   EMBL; CH471060; EAW91817.1; -; Genomic_DNA.
DR   RefSeq; NP_002559.2; NM_002568.3.
DR   RefSeq; XP_005250918.1; XM_005250861.2.
DR   Antibodypedia; 3159; 224 antibodies.
DR   GeneID; 26986; -.
DR   KEGG; hsa:26986; -.
DR   CTD; 26986; -.
DR   EuPathDB; HostDB:ENSG00000070756.13; -.
DR   eggNOG; KOG0123; Eukaryota.
DR   eggNOG; ENOG410XR5X; LUCA.
DR   KO; K13126; -.
DR   OMA; GRAQKKY; -.
DR   OrthoDB; 1027234at2759; -.
DR   ChiTaRS; PABPC1; human.
DR   GenomeRNAi; 26986; -.
DR   Bgee; ENSG00000070756; Expressed in testis and 229 other tissues.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-UniRule.
DR   Gene3D; 3.30.70.330; -; 4.
DR   InterPro; IPR012677; Nucleotide-bd_a/b_plait_sf.
DR   InterPro; IPR036053; PABP-dom.
DR   InterPro; IPR006515; PABP_1234.
DR   InterPro; IPR002004; PABP_HYD.
DR   InterPro; IPR035979; RBD_domain_sf.
DR   InterPro; IPR000504; RRM_dom.
DR   InterPro; IPR003954; RRM_dom_euk.
DR   Pfam; PF00658; PABP; 1.
DR   Pfam; PF00076; RRM_1; 4.
DR   SMART; SM00517; PolyA; 1.
DR   SMART; SM00360; RRM; 4.
DR   SMART; SM00361; RRM_1; 3.
DR   SUPFAM; SSF54928; SSF54928; 2.
DR   SUPFAM; SSF63570; SSF63570; 1.
DR   TIGRFAMs; TIGR01628; PABP-1234; 1.
DR   PROSITE; PS51309; PABC; 1.
DR   PROSITE; PS50102; RRM; 4.
PE   3: Inferred from homology;
KW   Cytoplasm {ECO:0000256|RuleBase:RU362004};
KW   Repeat {ECO:0000256|SAAS:SAAS00454674};
KW   RNA-binding {ECO:0000256|PROSITE-ProRule:PRU00176,
KW   ECO:0000256|RuleBase:RU362004, ECO:0000256|SAAS:SAAS00572889}.
FT   DOMAIN          11..89
FT                   /note="RRM"
FT                   /evidence="ECO:0000259|PROSITE:PS50102"
FT   DOMAIN          99..175
FT                   /note="RRM"
FT                   /evidence="ECO:0000259|PROSITE:PS50102"
FT   DOMAIN          191..268
FT                   /note="RRM"
FT                   /evidence="ECO:0000259|PROSITE:PS50102"
FT   DOMAIN          294..370
FT                   /note="RRM"
FT                   /evidence="ECO:0000259|PROSITE:PS50102"
FT   DOMAIN          542..619
FT                   /note="PABC"
FT                   /evidence="ECO:0000259|PROSITE:PS51309"
SQ   SEQUENCE   636 AA;  70671 MW;  2EB1B02A346132EE CRC64;
     MNPSAPSYPM ASLYVGDLHP DVTEAMLYEK FSPAGPILSI RVCRDMITRR SLGYAYVNFQ
     QPADAERALD TMNFDVIKGK PVRIMWSQRD PSLRKSGVGN IFIKNLDKSI DNKALYDTFS
     AFGNILSCKV VCDENGSKGY GFVHFETQEA AERAIEKMNG MLLNDRKVFV GRFKSRKERE
     AELGARAKEF TNVYIKNFGE DMDDERLKDL FGKFGPALSV KVMTDESGKS KGFGFVSFER
     HEDAQKAVDE MNGKELNGKQ IYVGRAQKKV ERQTELKRKF EQMKQDRITR YQGVNLYVKN
     LDDGIDDERL RKEFSPFGTI TSAKVMMEGG RSKGFGFVCF SSPEEATKAV TEMNGRIVAT
     KPLYVALAQR KEERQAHLTN QYMQRMASVR AVPNPVINPY QPAPPSGYFM AAIPQTQNRA
     AYYPPSQIAQ LRPSPRWTAQ GARPHPFQNM PGAIRPAAPR PPFSTMRPAS SQVPRVMSTQ
     RVANTSTQTM GPRPAAAAAA ATPAVRTVPQ YKYAAGVRNP QQHLNAQPQV TMQQPAVHVQ
     GQEPLTASML ASAPPQEQKQ MLGERLFPLI QAMHPTLAGK ITGMLLEIDN SELLHMLESP
     ESLRSKVDEA VAVLQAHQAK EAAQKAVNSA TGVPTV
//
ID   PABP1_HUMAN             Reviewed;         636 AA.
AC   P11940; Q15097; Q93004;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   22-APR-2020, entry version 243.
DE   RecName: Full=Polyadenylate-binding protein 1;
DE            Short=PABP-1;
DE            Short=Poly(A)-binding protein 1;
GN   Name=PABPC1; Synonyms=PAB1, PABP1, PABPC2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2885805; DOI=10.1093/nar/15.12.4771;
RA   Grange T., de Sa C.M., Oddos J., Pictet R.;
RT   "Human mRNA polyadenylate binding protein: evolutionary conservation of a
RT   nucleic acid binding motif.";
RL   Nucleic Acids Res. 15:4771-4787(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Lung;
RA   Hornstein E., Abramzon-Talianker A., Wiesel I., Meyuhas O.;
RT   "The human poly(A)-binding protein (PABP) gene: structural and functional
RT   analysis.";
RL   Submitted (SEP-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA   Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA   Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA   Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA   Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA   Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA   Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA   O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K.,
RA   Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA   Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA   Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA   Platzer M., Shimizu N., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 26-636 (ISOFORM 2).
RA   Murphy E.P., McKenna N.J., Headon D.R.;
RT   "Nucleotide sequence of a partial cDNA encoding a novel human
RT   polyadenylate-binding protein.";
RL   Submitted (FEB-1995) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   PROTEIN SEQUENCE OF 31-41; 51-78; 84-89; 96-104; 158-166; 189-196; 214-221;
RP   232-240; 291-309; 312-324; 357-370; 375-385; 482-506; 566-580 AND 605-620,
RP   METHYLATION AT ARG-493, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Colon carcinoma, and Ovarian carcinoma;
RA   Bienvenut W.V., Zebisch A., Lilla S., von Kriegsheim A., Lempens A.,
RA   Kolch W.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [7]
RP   PROTEIN SEQUENCE OF 31-41; 51-78; 84-89; 96-104; 114-129; 139-153; 158-166;
RP   187-208; 214-221; 232-240; 291-324; 334-348; 357-370; 375-385; 482-506;
RP   519-559; 566-620 AND 626-636, METHYLATION AT LYS-299 AND ARG-493, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RA   Bienvenut W.V., Waridel P., Quadroni M.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [8]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA], AND SUBCELLULAR LOCATION.
RX   PubMed=7908267; DOI=10.1006/excr.1994.1104;
RA   Goerlach M., Burd C.G., Dreyfuss G.;
RT   "The mRNA poly(A)-binding protein: localization, abundance, and RNA-binding
RT   specificity.";
RL   Exp. Cell Res. 211:400-407(1994).
RN   [9]
RP   SUBCELLULAR LOCATION.
RX   PubMed=9582337; DOI=10.1074/jbc.273.21.13015;
RA   Afonina E., Stauber R., Pavlakis G.N.;
RT   "The human poly(A)-binding protein 1 shuttles between the nucleus and the
RT   cytoplasm.";
RL   J. Biol. Chem. 273:13015-13021(1998).
RN   [10]
RP   INTERACTION WITH PAIP1, AND DOMAIN.
RX   PubMed=9548260; DOI=10.1038/33198;
RA   Craig A.W.B., Haghighat A., Yu A.T.K., Sonenberg N.;
RT   "Interaction of polyadenylate-binding protein with the eIF4G homologue PAIP
RT   enhances translation.";
RL   Nature 392:520-523(1998).
RN   [11]
RP   FUNCTION IN TRANSLATIONALLY COUPLED MRNA TURNOVER, AND IDENTIFICATION IN A
RP   COMPLEX WITH HNRPD; SYNCRIP; PAIP1 AND CSDE1.
RX   PubMed=11051545; DOI=10.1016/s0092-8674(00)00102-1;
RA   Grosset C., Chen C.-Y.A., Xu N., Sonenberg N., Jacquemin-Sablon H.,
RA   Shyu A.-B.;
RT   "A mechanism for translationally coupled mRNA turnover: interaction between
RT   the poly(A) tail and a c-fos RNA coding determinant via a protein
RT   complex.";
RL   Cell 103:29-40(2000).
RN   [12]
RP   INTERACTION WITH PAIP2.
RX   PubMed=11172725; DOI=10.1016/s1097-2765(01)00168-x;
RA   Khaleghpour K., Svitkin Y.V., Craig A.W.B., DeMaria C.T., Deo R.C.,
RA   Burley S.K., Sonenberg N.;
RT   "Translational repression by a novel partner of human poly(A) binding
RT   protein, Paip2.";
RL   Mol. Cell 7:205-216(2001).
RN   [13]
RP   INTERACTION WITH PAIP2.
RX   PubMed=11438674; DOI=10.1128/mcb.21.15.5200-5213.2001;
RA   Khaleghpour K., Kahvejian A., De Crescenzo G., Roy G., Svitkin Y.V.,
RA   Imataka H., O'Connor-McCourt M., Sonenberg N.;
RT   "Dual interactions of the translational repressor Paip2 with poly(A)
RT   binding protein.";
RL   Mol. Cell. Biol. 21:5200-5213(2001).
RN   [14]
RP   METHYLATION AT ARG-455 AND ARG-460, AND MUTAGENESIS OF ARG-455 AND ARG-460.
RX   PubMed=11850402; DOI=10.1093/embo-reports/kvf052;
RA   Lee J., Bedford M.T.;
RT   "PABP1 identified as an arginine methyltransferase substrate using high-
RT   density protein arrays.";
RL   EMBO Rep. 3:268-273(2002).
RN   [15]
RP   INTERACTION WITH PAIP1.
RX   PubMed=11997512; DOI=10.1128/mcb.22.11.3769-3782.2002;
RA   Roy G., De Crescenzo G., Khaleghpour K., Kahvejian A., O'Connor-McCourt M.,
RA   Sonenberg N.;
RT   "Paip1 interacts with poly(A) binding protein through two independent
RT   binding motifs.";
RL   Mol. Cell. Biol. 22:3769-3782(2002).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE SPLICEOSOMAL
RP   C COMPLEX.
RX   PubMed=11991638; DOI=10.1017/s1355838202021088;
RA   Jurica M.S., Licklider L.J., Gygi S.P., Grigorieff N., Moore M.J.;
RT   "Purification and characterization of native spliceosomes suitable for
RT   three-dimensional structural analysis.";
RL   RNA 8:426-439(2002).
RN   [17]
RP   PHOSPHORYLATION BY MAPKAPK2.
RX   PubMed=12565831; DOI=10.1016/s0006-291x(03)00015-9;
RA   Bollig F., Winzen R., Gaestel M., Kostka S., Resch K., Holtmann H.;
RT   "Affinity purification of ARE-binding proteins identifies polyA-binding
RT   protein 1 as a potential substrate in MK2-induced mRNA stabilization.";
RL   Biochem. Biophys. Res. Commun. 301:665-670(2003).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [19]
RP   INTERACTION WITH CSDE1.
RX   PubMed=15314026; DOI=10.1101/gad.1219104;
RA   Chang T.-C., Yamashita A., Chen C.-Y.A., Yamashita Y., Zhu W., Durdan S.,
RA   Kahvejian A., Sonenberg N., Shyu A.-B.;
RT   "UNR, a new partner of poly(A)-binding protein, plays a key role in
RT   translationally coupled mRNA turnover mediated by the c-fos major coding-
RT   region determinant.";
RL   Genes Dev. 18:2010-2023(2004).
RN   [20]
RP   IDENTIFICATION IN A MRNP COMPLEX WITH IGF2BP1 AND CSDE1.
RX   PubMed=16356927; DOI=10.1093/nar/gki1014;
RA   Patel G.P., Ma S., Bag J.;
RT   "The autoregulatory translational control element of poly(A)-binding
RT   protein mRNA forms a heteromeric ribonucleoprotein complex.";
RL   Nucleic Acids Res. 33:7074-7089(2005).
RN   [21]
RP   FUNCTION, HOMODIMERIZATION, INTERACTION WITH IGF2BP1, AND RNA-BINDING.
RX   PubMed=17212783; DOI=10.1111/j.1742-4658.2006.05556.x;
RA   Patel G.P., Bag J.;
RT   "IMP1 interacts with poly(A)-binding protein (PABP) and the autoregulatory
RT   translational control element of PABP-mRNA through the KH III-IV domain.";
RL   FEBS J. 273:5678-5690(2006).
RN   [22]
RP   INTERACTION WITH PAIP2B.
RX   PubMed=16804161; DOI=10.1261/rna.106506;
RA   Berlanga J.J., Baass A., Sonenberg N.;
RT   "Regulation of poly(A) binding protein function in translation:
RT   Characterization of the Paip2 homolog, Paip2B.";
RL   RNA 12:1556-1568(2006).
RN   [23]
RP   INTERACTION WITH AGO1 AND AGO2.
RX   PubMed=17932509; DOI=10.1038/sj.embor.7401088;
RA   Hoeck J., Weinmann L., Ender C., Ruedel S., Kremmer E., Raabe M.,
RA   Urlaub H., Meister G.;
RT   "Proteomic and functional analysis of Argonaute-containing mRNA-protein
RT   complexes in human cells.";
RL   EMBO Rep. 8:1052-1060(2007).
RN   [24]
RP   INTERACTION WITH NFX1.
RX   PubMed=17267499; DOI=10.1128/jvi.02007-06;
RA   Katzenellenbogen R.A., Egelkrout E.M., Vliet-Gregg P., Gewin L.C.,
RA   Gafken P.R., Galloway D.A.;
RT   "NFX1-123 and poly(A) binding proteins synergistically augment activation
RT   of telomerase in human papillomavirus type 16 E6-expressing cells.";
RL   J. Virol. 81:3786-3796(2007).
RN   [25]
RP   IDENTIFICATION IN A MRNP GRANULE COMPLEX, INTERACTION WITH IGF2BP1, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=17289661; DOI=10.1074/mcp.m600346-mcp200;
RA   Joeson L., Vikesaa J., Krogh A., Nielsen L.K., Hansen T., Borup R.,
RA   Johnsen A.H., Christiansen J., Nielsen F.C.;
RT   "Molecular composition of IMP1 ribonucleoprotein granules.";
RL   Mol. Cell. Proteomics 6:798-811(2007).
RN   [26]
RP   SUBCELLULAR LOCATION.
RX   PubMed=18799579; DOI=10.1128/jvi.00872-08;
RA   Harb M., Becker M.M., Vitour D., Baron C.H., Vende P., Brown S.C.,
RA   Bolte S., Arold S.T., Poncet D.;
RT   "Nuclear localization of cytoplasmic poly(A)-binding protein upon rotavirus
RT   infection involves the interaction of NSP3 with eIF4G and RoXaN.";
RL   J. Virol. 82:11283-11293(2008).
RN   [27]
RP   INTERACTION WITH DDX3X AND NXF1, AND SUBCELLULAR LOCATION.
RX   PubMed=18596238; DOI=10.1091/mbc.e07-12-1264;
RA   Lai M.C., Lee Y.H., Tarn W.Y.;
RT   "The DEAD-box RNA helicase DDX3 associates with export messenger
RT   ribonucleoproteins as well as tip-associated protein and participates in
RT   translational control.";
RL   Mol. Biol. Cell 19:3847-3858(2008).
RN   [28]
RP   FUNCTION IN NONSENSE-MEDIATED MRNA DECAY, AND INTERACTION WITH GSPT2.
RX   PubMed=18447585; DOI=10.1371/journal.pbio.0060111;
RA   Singh G., Rebbapragada I., Lykke-Andersen J.;
RT   "A competition between stimulators and antagonists of Upf complex
RT   recruitment governs human nonsense-mediated mRNA decay.";
RL   PLoS Biol. 6:E111-E111(2008).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [30]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [31]
RP   IDENTIFICATION IN A MRNP COMPLEX, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=19029303; DOI=10.1261/rna.1175909;
RA   Weidensdorfer D., Stoehr N., Baude A., Lederer M., Koehn M., Schierhorn A.,
RA   Buchmeier S., Wahle E., Huettelmaiery S.;
RT   "Control of c-myc mRNA stability by IGF2BP1-associated cytoplasmic RNPs.";
RL   RNA 15:104-115(2009).
RN   [32]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-512, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [33]
RP   REVIEW.
RX   PubMed=20102337; DOI=10.1042/bj20091571;
RA   Smith R.W., Gray N.K.;
RT   "Poly(A)-binding protein (PABP): a common viral target.";
RL   Biochem. J. 426:1-12(2010).
RN   [34]
RP   INTERACTION WITH LARP1.
RX   PubMed=20430826; DOI=10.1093/nar/gkq294;
RA   Burrows C., Abd Latip N., Lam S.J., Carpenter L., Sawicka K., Tzolovsky G.,
RA   Gabra H., Bushell M., Glover D.M., Willis A.E., Blagden S.P.;
RT   "The RNA binding protein Larp1 regulates cell division, apoptosis and cell
RT   migration.";
RL   Nucleic Acids Res. 38:5542-5553(2010).
RN   [35]
RP   INTERACTION WITH HHV-5 PROTEIN UL69.
RX   PubMed=20133758; DOI=10.1073/pnas.0914856107;
RA   Aoyagi M., Gaspar M., Shenk T.E.;
RT   "Human cytomegalovirus UL69 protein facilitates translation by associating
RT   with the mRNA cap-binding complex and excluding 4EBP1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:2640-2645(2010).
RN   [36]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PABPC1 AND RACK1.
RX   PubMed=20573744; DOI=10.1261/rna.2146910;
RA   Schaffler K., Schulz K., Hirmer A., Wiesner J., Grimm M., Sickmann A.,
RA   Fischer U.;
RT   "A stimulatory role for the La-related protein 4B in translation.";
RL   RNA 16:1488-1499(2010).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [39]
RP   INTERACTION WITH SETX.
RX   PubMed=21700224; DOI=10.1016/j.molcel.2011.04.026;
RA   Skourti-Stathaki K., Proudfoot N.J., Gromak N.;
RT   "Human senataxin resolves RNA/DNA hybrids formed at transcriptional pause
RT   sites to promote Xrn2-dependent termination.";
RL   Mol. Cell 42:794-805(2011).
RN   [40]
RP   INTERACTION WITH DDX3X, AND SUBCELLULAR LOCATION.
RX   PubMed=21883093; DOI=10.1042/bj20110739;
RA   Shih J.W., Wang W.T., Tsai T.Y., Kuo C.Y., Li H.K., Wu Lee Y.H.;
RT   "Critical roles of RNA helicase DDX3 and its interactions with eIF4E/PABP1
RT   in stress granule assembly and stress response.";
RL   Biochem. J. 441:119-129(2012).
RN   [41]
RP   INTERACTION WITH DDX3X, AND SUBCELLULAR LOCATION.
RX   PubMed=22872150; DOI=10.1038/emboj.2012.220;
RA   Soto-Rifo R., Rubilar P.S., Limousin T., de Breyne S., Decimo D.,
RA   Ohlmann T.;
RT   "DEAD-box protein DDX3 associates with eIF4F to promote translation of
RT   selected mRNAs.";
RL   EMBO J. 31:3745-3756(2012).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315 AND THR-319, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [43]
RP   INTERACTION WITH TRIM71.
RX   PubMed=23125361; DOI=10.1093/nar/gks1032;
RA   Loedige I., Gaidatzis D., Sack R., Meister G., Filipowicz W.;
RT   "The mammalian TRIM-NHL protein TRIM71/LIN-41 is a repressor of mRNA
RT   function.";
RL   Nucleic Acids Res. 41:518-532(2013).
RN   [44]
RP   INTERACTION WITH G3BP1 AND G3BP2.
RX   PubMed=23279204; DOI=10.1111/gtc.12023;
RA   Matsuki H., Takahashi M., Higuchi M., Makokha G.N., Oie M., Fujii M.;
RT   "Both G3BP1 and G3BP2 contribute to stress granule formation.";
RL   Genes Cells 18:135-146(2013).
RN   [45]
RP   FUNCTION.
RX   PubMed=25480299; DOI=10.1016/j.cell.2014.10.055;
RA   Lim J., Ha M., Chang H., Kwon S.C., Simanshu D.K., Patel D.J., Kim V.N.;
RT   "Uridylation by TUT4 and TUT7 marks mRNA for degradation.";
RL   Cell 159:1365-1376(2014).
RN   [46]
RP   INTERACTION WITH LARP1.
RX   PubMed=24532714; DOI=10.1101/gad.231407.113;
RA   Tcherkezian J., Cargnello M., Romeo Y., Huttlin E.L., Lavoie G., Gygi S.P.,
RA   Roux P.P.;
RT   "Proteomic analysis of cap-dependent translation identifies LARP1 as a key
RT   regulator of 5'TOP mRNA translation.";
RL   Genes Dev. 28:357-371(2014).
RN   [47]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-385; ARG-419; ARG-432; ARG-436;
RP   ARG-481; ARG-493; ARG-506 AND ARG-518, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [48]
RP   INTERACTION WITH LARP1.
RX   PubMed=25940091; DOI=10.1074/jbc.m114.621730;
RA   Fonseca B.D., Zakaria C., Jia J.J., Graber T.E., Svitkin Y., Tahmasebi S.,
RA   Healy D., Hoang H.D., Jensen J.M., Diao I.T., Lussier A., Dajadian C.,
RA   Padmanabhan N., Wang W., Matta-Camacho E., Hearnden J., Smith E.M.,
RA   Tsukumo Y., Yanagiya A., Morita M., Petroulakis E., Gonzalez J.L.,
RA   Hernandez G., Alain T., Damgaard C.K.;
RT   "La-related protein 1 (LARP1) represses terminal oligopyrimidine (TOP) mRNA
RT   translation downstream of mTOR complex 1 (mTORC1).";
RL   J. Biol. Chem. 290:15996-16020(2015).
RN   [49]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [50]
RP   INTERACTION WITH ZFC3H1.
RX   PubMed=27871484; DOI=10.1016/j.molcel.2016.09.025;
RA   Meola N., Domanski M., Karadoulama E., Chen Y., Gentil C., Pultz D.,
RA   Vitting-Seerup K., Lykke-Andersen S., Andersen J.S., Sandelin A.,
RA   Jensen T.H.;
RT   "Identification of a nuclear exosome decay pathway for processed
RT   transcripts.";
RL   Mol. Cell 64:520-533(2016).
RN   [51]
RP   IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION (MICROBIAL INFECTION),
RP   INTERACTION WITH SHFL, AND IDENTIFICATION IN A COMPLEX WITH SHFL AND LARP1.
RX   PubMed=26735137; DOI=10.1371/journal.ppat.1005357;
RA   Suzuki Y., Chin W.X., Han Q., Ichiyama K., Lee C.H., Eyo Z.W., Ebina H.,
RA   Takahashi H., Takahashi C., Tan B.H., Hishiki T., Ohba K., Matsuyama T.,
RA   Koyanagi Y., Tan Y.J., Sawasaki T., Chu J.J., Vasudevan S.G., Sano K.,
RA   Yamamoto N.;
RT   "Characterization of RyDEN (C19orf66) as an interferon-stimulated cellular
RT   inhibitor against dengue virus replication.";
RL   PLoS Pathog. 12:E1005357-E1005357(2016).
RN   [52]
RP   INTERACTION WITH DDX3X, AND SUBCELLULAR LOCATION.
RX   PubMed=28733330; DOI=10.1042/bcj20170354;
RA   Copsey A.C., Cooper S., Parker R., Lineham E., Lapworth C., Jallad D.,
RA   Sweet S., Morley S.J.;
RT   "The helicase, DDX3X, interacts with poly(A)-binding protein 1 (PABP1) and
RT   caprin-1 at the leading edge of migrating fibroblasts and is required for
RT   efficient cell spreading.";
RL   Biochem. J. 474:3109-3120(2017).
RN   [53]
RP   INTERACTION WITH TENT5C.
RX   PubMed=28931820; DOI=10.1038/s41467-017-00578-5;
RA   Mroczek S., Chlebowska J., Kulinski T.M., Gewartowska O., Gruchota J.,
RA   Cysewski D., Liudkovska V., Borsuk E., Nowis D., Dziembowski A.;
RT   "The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in
RT   multiple myeloma.";
RL   Nat. Commun. 8:619-619(2017).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 1-190.
RX   PubMed=10499800; DOI=10.1016/s0092-8674(00)81517-2;
RA   Deo R.C., Bonanno J.B., Sonenberg N., Burley S.K.;
RT   "Recognition of polyadenylate RNA by the poly(A)-binding protein.";
RL   Cell 98:835-845(1999).
RN   [55]
RP   STRUCTURE BY NMR OF 498-636, INTERACTION WITH GSPT1; PAIP1 AND PAIP2, AND
RP   DOMAIN.
RX   PubMed=11287632; DOI=10.1073/pnas.071024998;
RA   Kozlov G., Trempe J.F., Khaleghpour K., Kahvejian A., Ekiel I., Gehring K.;
RT   "Structure and function of the C-terminal PABC domain of human poly(A)-
RT   binding protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:4409-4413(2001).
RN   [56]
RP   STRUCTURE BY NMR OF 541-623 IN COMPLEX WITH GSPT1.
RA   Osawa M., Nakanishi T., Hosoda N., Uchida S., Hoshino T., Katada I.,
RA   Shimada I.;
RT   "Eukaryotic translation termination factor Gspt/ERF3 recognizes Pabp with
RT   chemical exchange using two overlapping motifs.";
RL   Submitted (MAY-2009) to the PDB data bank.
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 544-626 IN COMPLEX WITH PAIP2, AND
RP   DOMAIN.
RX   PubMed=20096703; DOI=10.1016/j.jmb.2010.01.032;
RA   Kozlov G., Menade M., Rosenauer A., Nguyen L., Gehring K.;
RT   "Molecular determinants of PAM2 recognition by the MLLE domain of poly(A)-
RT   binding protein.";
RL   J. Mol. Biol. 397:397-407(2010).
RN   [58]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 543-621 IN COMPLEX WITH LARP4B.
RA   Grimm C., Pelz J.P.;
RT   "LARP4B binds to the PABC1 MLLE domain via a variant PAM2 motif.";
RL   Submitted (DEC-2010) to the PDB data bank.
RN   [59]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 544-626 IN COMPLEX WITH LARP4.
RX   PubMed=21098120; DOI=10.1128/mcb.01162-10;
RA   Yang R., Gaidamakov S.A., Xie J., Lee J., Martino L., Kozlov G.,
RA   Crawford A.K., Russo A.N., Conte M.R., Gehring K., Maraia R.J.;
RT   "La-related protein 4 binds poly(A), interacts with the poly(A)-binding
RT   protein MLLE domain via a variant PAM2w motif, and can promote mRNA
RT   stability.";
RL   Mol. Cell. Biol. 31:542-556(2011).
CC   -!- FUNCTION: Binds the poly(A) tail of mRNA, including that of its own
CC       transcript, and regulates processes of mRNA metabolism such as pre-mRNA
CC       splicing and mRNA stability (PubMed:11051545, PubMed:17212783,
CC       PubMed:25480299). Its function in translational initiation regulation
CC       can either be enhanced by PAIP1 or repressed by PAIP2 (PubMed:11051545,
CC       PubMed:20573744). Can probably bind to cytoplasmic RNA sequences other
CC       than poly(A) in vivo. Involved in translationally coupled mRNA turnover
CC       (PubMed:11051545). Implicated with other RNA-binding proteins in the
CC       cytoplasmic deadenylation/translational and decay interplay of the FOS
CC       mRNA mediated by the major coding-region determinant of instability
CC       (mCRD) domain (PubMed:11051545). Involved in regulation of nonsense-
CC       mediated decay (NMD) of mRNAs containing premature stop codons; for the
CC       recognition of premature termination codons (PTC) and initiation of NMD
CC       a competitive interaction between UPF1 and PABPC1 with the ribosome-
CC       bound release factors is proposed (PubMed:18447585). By binding to long
CC       poly(A) tails, may protect them from uridylation by ZCCHC6/ZCCHC11 and
CC       hence contribute to mRNA stability (PubMed:25480299).
CC       {ECO:0000269|PubMed:11051545, ECO:0000269|PubMed:17212783,
CC       ECO:0000269|PubMed:18447585, ECO:0000269|PubMed:20573744,
CC       ECO:0000269|PubMed:25480299}.
CC   -!- FUNCTION: (Microbial infection) Positively regulates the replication of
CC       dengue virus (DENV). {ECO:0000269|PubMed:26735137}.
CC   -!- SUBUNIT: May interact with SETX (PubMed:21700224). May form homodimers.
CC       Component of a multisubunit autoregulatory ribonucleoprotein complex
CC       (ARC), at least composed of IGF2BP1, PABPC1 and CSDE1
CC       (PubMed:16356927). Directly interacts with IGF2BP1. Part of a complex
CC       associated with the FOS mCRD domain and consisting of HNRPD, SYNCRIP,
CC       PAIP1 and CSDE1/UNR (PubMed:11051545). Interacts with the PABPC1-
CC       interacting motif-1 (PAM1) and -2 (PAM2) of PAIP1 and PAIP2
CC       (PubMed:9548260, PubMed:11172725, PubMed:11438674, PubMed:11997512,
CC       PubMed:11287632, PubMed:20096703). Interacts with PAIP1 with a 1:1
CC       stoichiometry and with PAIP2 with a 1:2 stoichiometry. The interaction
CC       with CSDE1 is direct and RNA-independent. Found in a mRNP complex with
CC       YBX2 (By similarity). Interacts with TENT2/GLD2 (By similarity).
CC       Identified in the spliceosome C complex (PubMed:11991638). Identified
CC       in a mRNP complex, at least composed of DHX9, DDX3X, ELAVL1, HNRNPU,
CC       IGF2BP1, ILF3, PABPC1, PCBP2, PTBP2, STAU1, STAU2, SYNCRIP and YBX1.
CC       The interaction with DDX3X is direct and RNA-independent
CC       (PubMed:18596238, PubMed:21883093, PubMed:22872150). This interaction
CC       increases in stressed cells and decreases during cell recovery
CC       (PubMed:21883093). Identified in a IGF2BP1-dependent mRNP granule
CC       complex containing untranslated mRNAs. Interacts with NXF1/TAP
CC       (PubMed:17267499, PubMed:18596238). Interacts with PIWIL1 (By
CC       similarity). Interacts with AGO1, AGO2, GSPT1 and GSPT2
CC       (PubMed:17932509, PubMed:18447585, Ref.56). Interacts with LARP4B
CC       (Ref.58). Interacts (via the second and third RRM domains and the C-
CC       terminus) with PAIP2B (via central acidic portion and C-terminus)
CC       (PubMed:16804161, PubMed:11287632). Forms a complex with LARP1 and SHFL
CC       (PubMed:20430826, PubMed:24532714, PubMed:25940091, PubMed:26735137).
CC       Interacts with LARP4 (PubMed:21098120). Interacts with ZFC3H1 in a
CC       RNase-sensitive manner (PubMed:27871484). Interacts with TRIM71 (via
CC       NHL repeats) in an RNA-dependent manner (PubMed:23125361). Interacts
CC       with TENT5C; the interaction has no effect on TENT5C poly(A) polymerase
CC       function (PubMed:28931820). Interacts with G3BP1 and G3BP2
CC       (PubMed:23279204). {ECO:0000250|UniProtKB:P29341,
CC       ECO:0000269|PubMed:11051545, ECO:0000269|PubMed:11172725,
CC       ECO:0000269|PubMed:11287632, ECO:0000269|PubMed:11438674,
CC       ECO:0000269|PubMed:11991638, ECO:0000269|PubMed:11997512,
CC       ECO:0000269|PubMed:15314026, ECO:0000269|PubMed:16356927,
CC       ECO:0000269|PubMed:16804161, ECO:0000269|PubMed:17212783,
CC       ECO:0000269|PubMed:17267499, ECO:0000269|PubMed:17289661,
CC       ECO:0000269|PubMed:17932509, ECO:0000269|PubMed:18447585,
CC       ECO:0000269|PubMed:18596238, ECO:0000269|PubMed:19029303,
CC       ECO:0000269|PubMed:20096703, ECO:0000269|PubMed:20133758,
CC       ECO:0000269|PubMed:20430826, ECO:0000269|PubMed:20573744,
CC       ECO:0000269|PubMed:21098120, ECO:0000269|PubMed:21700224,
CC       ECO:0000269|PubMed:21883093, ECO:0000269|PubMed:22872150,
CC       ECO:0000269|PubMed:23125361, ECO:0000269|PubMed:23279204,
CC       ECO:0000269|PubMed:24532714, ECO:0000269|PubMed:26735137,
CC       ECO:0000269|PubMed:27871484, ECO:0000269|PubMed:28931820,
CC       ECO:0000269|PubMed:9548260, ECO:0000269|Ref.56}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human
CC       cytomegalovirus/HHV-5 protein UL69. {ECO:0000269|PubMed:20133758}.
CC   -!- INTERACTION:
CC       P11940; Q99700: ATXN2; NbExp=6; IntAct=EBI-81531, EBI-697691;
CC       P11940; O00571: DDX3X; NbExp=10; IntAct=EBI-81531, EBI-353779;
CC       P11940; P06730: EIF4E; NbExp=5; IntAct=EBI-81531, EBI-73440;
CC       P11940; Q04637: EIF4G1; NbExp=4; IntAct=EBI-81531, EBI-73711;
CC       P11940; P15170-2: GSPT1; NbExp=2; IntAct=EBI-81531, EBI-9094806;
CC       P11940; Q8IYD1: GSPT2; NbExp=7; IntAct=EBI-81531, EBI-3869637;
CC       P11940; Q14103-4: HNRNPD; NbExp=2; IntAct=EBI-81531, EBI-432545;
CC       P11940; P35568: IRS1; NbExp=2; IntAct=EBI-81531, EBI-517592;
CC       P11940; Q09161: NCBP1; NbExp=4; IntAct=EBI-81531, EBI-464743;
CC       P11940; Q86U42: PABPN1; NbExp=2; IntAct=EBI-81531, EBI-1226435;
CC       P11940; Q9H074: PAIP1; NbExp=13; IntAct=EBI-81531, EBI-81519;
CC       P11940; Q9BPZ3: PAIP2; NbExp=5; IntAct=EBI-81531, EBI-2957445;
CC       P11940; Q58A45: PAN3; NbExp=4; IntAct=EBI-81531, EBI-2513054;
CC       P11940; Q96Q15: SMG1; NbExp=2; IntAct=EBI-81531, EBI-1049832;
CC       P11940; Q8NDV7: TNRC6A; NbExp=3; IntAct=EBI-81531, EBI-2269715;
CC       P11940; Q9UPQ9: TNRC6B; NbExp=3; IntAct=EBI-81531, EBI-947158;
CC       P11940; Q9HCJ0: TNRC6C; NbExp=22; IntAct=EBI-81531, EBI-6507625;
CC       P11940; P50616: TOB1; NbExp=4; IntAct=EBI-81531, EBI-723281;
CC       P11940; Q14106: TOB2; NbExp=4; IntAct=EBI-81531, EBI-2562000;
CC       P11940; Q9J0X9: UL54; Xeno; NbExp=3; IntAct=EBI-81531, EBI-7967856;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:20573744,
CC       ECO:0000269|PubMed:21883093, ECO:0000269|PubMed:28733330,
CC       ECO:0000269|PubMed:7908267, ECO:0000269|PubMed:9582337}. Cytoplasm,
CC       Stress granule {ECO:0000269|PubMed:21883093,
CC       ECO:0000269|PubMed:22872150}. Nucleus {ECO:0000269|PubMed:18799579,
CC       ECO:0000269|PubMed:9582337}. Cell projection, lamellipodium
CC       {ECO:0000269|PubMed:28733330}. Note=Localized in cytoplasmic mRNP
CC       granules containing untranslated mRNAs (PubMed:17289661). Shuttles
CC       between the cytoplasm and the nucleus (PubMed:9582337). During stress
CC       and in the absence of DDX3X, localizes to the nucleus
CC       (PubMed:21883093). At the leading edge of migrating fibroblasts,
CC       colocalizes with DDX3X (PubMed:28733330). {ECO:0000269|PubMed:17289661,
CC       ECO:0000269|PubMed:21883093, ECO:0000269|PubMed:28733330,
CC       ECO:0000269|PubMed:9582337}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P11940-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P11940-2; Sequence=VSP_009846;
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- DOMAIN: The RNA-binding domains RRM1 and RRM2 and the C-terminus (last
CC       138 amino acids) regions interact with the PABPC1-interacting motif-1
CC       (PAM1) and -2 (PAM2) of PAIP1, respectively.
CC       {ECO:0000269|PubMed:11287632, ECO:0000269|PubMed:11997512}.
CC   -!- DOMAIN: The RNA-binding domains RRM2 and RRM3 and the C-terminus (last
CC       138 amino acids) regions interact with the PABPC1-interacting motif-1
CC       (PAM1) and -2 (PAM2) of PAIP2, respectively.
CC       {ECO:0000269|PubMed:11287632, ECO:0000269|PubMed:20096703}.
CC   -!- PTM: Phosphorylated by MAPKAPK2. {ECO:0000269|PubMed:12565831}.
CC   -!- PTM: Methylated by CARM1. Arg-493 is dimethylated, probably to
CC       asymmetric dimethylarginine. {ECO:0000269|PubMed:11850402,
CC       ECO:0000269|Ref.6, ECO:0000269|Ref.7}.
CC   -!- MISCELLANEOUS: Many viruses shutoff host mRNA translational machinery
CC       by inhibiting cellular PABPC1 activity using different mechanisms.
CC       Picornaviruses, caliciviruses or lentiviruses encode proteases that
CC       cleave PABPC1 at several defined sites in the proline-rich linker
CC       region between RRMs and the C-terminal domain. Rotaviruses,
CC       gammherpesviruses and bunyamwera virus relocalize PABPC1 from the
CC       cytoplasm to the nucleus thus altering its function. Many of these
CC       viruses translate their mRNA in a PABPC1-independent manner and are
CC       unaffected by host PABPC1 inhibition.
CC   -!- SIMILARITY: Belongs to the polyadenylate-binding protein type-1 family.
CC       {ECO:0000305}.
CC   -!- CAUTION: Was termed (Ref.5) polyadenylate binding protein II.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y00345; CAA68428.1; -; mRNA.
DR   EMBL; U68104; AAD08718.1; -; Genomic_DNA.
DR   EMBL; U68093; AAD08718.1; JOINED; Genomic_DNA.
DR   EMBL; U68094; AAD08718.1; JOINED; Genomic_DNA.
DR   EMBL; U68095; AAD08718.1; JOINED; Genomic_DNA.
DR   EMBL; U68097; AAD08718.1; JOINED; Genomic_DNA.
DR   EMBL; U68098; AAD08718.1; JOINED; Genomic_DNA.
DR   EMBL; U68099; AAD08718.1; JOINED; Genomic_DNA.
DR   EMBL; U68100; AAD08718.1; JOINED; Genomic_DNA.
DR   EMBL; U68101; AAD08718.1; JOINED; Genomic_DNA.
DR   EMBL; U68102; AAD08718.1; JOINED; Genomic_DNA.
DR   EMBL; U68103; AAD08718.1; JOINED; Genomic_DNA.
DR   EMBL; AP001205; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC015958; AAH15958.1; -; mRNA.
DR   EMBL; BC023520; AAH23520.1; -; mRNA.
DR   EMBL; Z48501; CAA88401.1; -; mRNA.
DR   CCDS; CCDS6289.1; -. [P11940-1]
DR   PIR; A93668; DNHUPA.
DR   PIR; S52491; S52491.
DR   RefSeq; NP_002559.2; NM_002568.3. [P11940-1]
DR   RefSeq; XP_005250918.1; XM_005250861.2. [P11940-1]
DR   PDB; 1CVJ; X-ray; 2.60 A; A/B/C/D/E/F/G/H=1-190.
DR   PDB; 1G9L; NMR; -; A=498-636.
DR   PDB; 1JGN; NMR; -; A=544-636.
DR   PDB; 1JH4; NMR; -; A=544-636.
DR   PDB; 2K8G; NMR; -; A=90-182.
DR   PDB; 2RQG; NMR; -; B=541-623.
DR   PDB; 2RQH; NMR; -; B=541-623.
DR   PDB; 2X04; X-ray; 1.49 A; A/B=545-619.
DR   PDB; 3KTP; X-ray; 1.50 A; A=544-626.
DR   PDB; 3KTR; X-ray; 1.70 A; A=544-626.
DR   PDB; 3KUI; X-ray; 2.30 A; A=544-626.
DR   PDB; 3KUJ; X-ray; 1.40 A; A=544-626.
DR   PDB; 3KUR; X-ray; 2.50 A; A/B/C/D/E/F/G/H=544-617.
DR   PDB; 3KUS; X-ray; 1.40 A; A/B=544-626.
DR   PDB; 3KUT; X-ray; 1.50 A; A/B=544-626.
DR   PDB; 3PKN; X-ray; 1.80 A; A=544-626.
DR   PDB; 3PTH; X-ray; 1.70 A; A=543-621.
DR   PDB; 4F02; X-ray; 2.00 A; A/D=1-190.
DR   PDB; 4F25; X-ray; 1.90 A; A=99-199.
DR   PDB; 4F26; X-ray; 2.00 A; A=99-199.
DR   PDB; 5DX1; X-ray; 1.93 A; F/G/H/I=449-466.
DR   PDB; 5DX8; X-ray; 1.94 A; E/F/G/H=449-466.
DR   PDB; 5DXA; X-ray; 2.07 A; F/G/I=449-466.
DR   PDB; 5LGP; X-ray; 2.04 A; E/F/G/H=447-458.
DR   PDB; 5LGQ; X-ray; 2.11 A; E/F/G/H=456-466.
DR   PDB; 5LGR; X-ray; 2.00 A; E/F/G/H=447-458.
DR   PDB; 5LGS; X-ray; 2.10 A; E/F/G/H=456-464.
DR   PDBsum; 1CVJ; -.
DR   PDBsum; 1G9L; -.
DR   PDBsum; 1JGN; -.
DR   PDBsum; 1JH4; -.
DR   PDBsum; 2K8G; -.
DR   PDBsum; 2RQG; -.
DR   PDBsum; 2RQH; -.
DR   PDBsum; 2X04; -.
DR   PDBsum; 3KTP; -.
DR   PDBsum; 3KTR; -.
DR   PDBsum; 3KUI; -.
DR   PDBsum; 3KUJ; -.
DR   PDBsum; 3KUR; -.
DR   PDBsum; 3KUS; -.
DR   PDBsum; 3KUT; -.
DR   PDBsum; 3PKN; -.
DR   PDBsum; 3PTH; -.
DR   PDBsum; 4F02; -.
DR   PDBsum; 4F25; -.
DR   PDBsum; 4F26; -.
DR   PDBsum; 5DX1; -.
DR   PDBsum; 5DX8; -.
DR   PDBsum; 5DXA; -.
DR   PDBsum; 5LGP; -.
DR   PDBsum; 5LGQ; -.
DR   PDBsum; 5LGR; -.
DR   PDBsum; 5LGS; -.
DR   SMR; P11940; -.
DR   BioGrid; 117939; 316.
DR   ComplexPortal; CPX-1076; mCRD-poly(A)-bridging complex.
DR   CORUM; P11940; -.
DR   DIP; DIP-31613N; -.
DR   ELM; P11940; -.
DR   IntAct; P11940; 163.
DR   MINT; P11940; -.
DR   STRING; 9606.ENSP00000313007; -.
DR   BindingDB; P11940; -.
DR   ChEMBL; CHEMBL1293286; -.
DR   MoonDB; P11940; Predicted.
DR   iPTMnet; P11940; -.
DR   MetOSite; P11940; -.
DR   PhosphoSitePlus; P11940; -.
DR   SwissPalm; P11940; -.
DR   BioMuta; PABPC1; -.
DR   DMDM; 3183544; -.
DR   EPD; P11940; -.
DR   jPOST; P11940; -.
DR   MassIVE; P11940; -.
DR   MaxQB; P11940; -.
DR   PaxDb; P11940; -.
DR   PeptideAtlas; P11940; -.
DR   PRIDE; P11940; -.
DR   ProteomicsDB; 52814; -. [P11940-1]
DR   ProteomicsDB; 52815; -. [P11940-2]
DR   Antibodypedia; 3159; 224 antibodies.
DR   DNASU; 26986; -.
DR   Ensembl; ENST00000318607; ENSP00000313007; ENSG00000070756. [P11940-1]
DR   GeneID; 26986; -.
DR   KEGG; hsa:26986; -.
DR   UCSC; uc003yjs.2; human. [P11940-1]
DR   CTD; 26986; -.
DR   DisGeNET; 26986; -.
DR   GeneCards; PABPC1; -.
DR   HGNC; HGNC:8554; PABPC1.
DR   HPA; ENSG00000070756; Low tissue specificity.
DR   MIM; 604679; gene.
DR   neXtProt; NX_P11940; -.
DR   OpenTargets; ENSG00000070756; -.
DR   PharmGKB; PA32880; -.
DR   eggNOG; KOG0123; Eukaryota.
DR   eggNOG; ENOG410XR5X; LUCA.
DR   GeneTree; ENSGT00940000153773; -.
DR   InParanoid; P11940; -.
DR   KO; K13126; -.
DR   OMA; GRAQKKY; -.
DR   PhylomeDB; P11940; -.
DR   TreeFam; TF300458; -.
DR   Reactome; R-HSA-156827; L13a-mediated translational silencing of Ceruloplasmin expression.
DR   Reactome; R-HSA-429947; Deadenylation of mRNA.
DR   Reactome; R-HSA-450408; AUF1 (hnRNP D0) binds and destabilizes mRNA.
DR   Reactome; R-HSA-72649; Translation initiation complex formation.
DR   Reactome; R-HSA-9010553; Regulation of expression of SLITs and ROBOs.
DR   Reactome; R-HSA-975956; Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC).
DR   Reactome; R-HSA-975957; Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC).
DR   SIGNOR; P11940; -.
DR   ChiTaRS; PABPC1; human.
DR   EvolutionaryTrace; P11940; -.
DR   GeneWiki; PABPC1; -.
DR   GenomeRNAi; 26986; -.
DR   Pharos; P11940; Tbio.
DR   PRO; PR:P11940; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; P11940; protein.
DR   Bgee; ENSG00000070756; Expressed in testis and 229 other tissues.
DR   ExpressionAtlas; P11940; baseline and differential.
DR   Genevisible; P11940; HS.
DR   GO; GO:0071013; C:catalytic step 2 spliceosome; IDA:UniProtKB.
DR   GO; GO:0031252; C:cell leading edge; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0036464; C:cytoplasmic ribonucleoprotein granule; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0010494; C:cytoplasmic stress granule; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IDA:UniProtKB.
DR   GO; GO:0003730; F:mRNA 3'-UTR binding; IDA:UniProtKB.
DR   GO; GO:0008143; F:poly(A) binding; IDA:MGI.
DR   GO; GO:0008266; F:poly(U) RNA binding; IDA:MGI.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IDA:CAFA.
DR   GO; GO:0008494; F:translation activator activity; TAS:UniProtKB.
DR   GO; GO:0031047; P:gene silencing by RNA; ISS:UniProtKB.
DR   GO; GO:0006378; P:mRNA polyadenylation; TAS:UniProtKB.
DR   GO; GO:0000398; P:mRNA splicing, via spliceosome; IC:UniProtKB.
DR   GO; GO:0048255; P:mRNA stabilization; TAS:UniProtKB.
DR   GO; GO:2000623; P:negative regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay; IDA:UniProtKB.
DR   GO; GO:0000184; P:nuclear-transcribed mRNA catabolic process, nonsense-mediated decay; TAS:Reactome.
DR   GO; GO:1900153; P:positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay; ISS:UniProtKB.
DR   GO; GO:0060213; P:positive regulation of nuclear-transcribed mRNA poly(A) tail shortening; ISS:UniProtKB.
DR   GO; GO:0045070; P:positive regulation of viral genome replication; IMP:UniProtKB.
DR   GO; GO:0043488; P:regulation of mRNA stability; TAS:Reactome.
DR   GO; GO:0006413; P:translational initiation; TAS:Reactome.
DR   Gene3D; 3.30.70.330; -; 4.
DR   InterPro; IPR012677; Nucleotide-bd_a/b_plait_sf.
DR   InterPro; IPR036053; PABP-dom.
DR   InterPro; IPR006515; PABP_1234.
DR   InterPro; IPR002004; PABP_HYD.
DR   InterPro; IPR035979; RBD_domain_sf.
DR   InterPro; IPR000504; RRM_dom.
DR   InterPro; IPR003954; RRM_dom_euk.
DR   Pfam; PF00658; PABP; 1.
DR   Pfam; PF00076; RRM_1; 4.
DR   SMART; SM00517; PolyA; 1.
DR   SMART; SM00360; RRM; 4.
DR   SMART; SM00361; RRM_1; 3.
DR   SUPFAM; SSF54928; SSF54928; 2.
DR   SUPFAM; SSF63570; SSF63570; 1.
DR   TIGRFAMs; TIGR01628; PABP-1234; 1.
DR   PROSITE; PS51309; PABC; 1.
DR   PROSITE; PS50102; RRM; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cell projection;
KW   Cytoplasm; Direct protein sequencing; Methylation; mRNA processing;
KW   mRNA splicing; Nonsense-mediated mRNA decay; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; RNA-binding; Spliceosome.
FT   CHAIN           1..636
FT                   /note="Polyadenylate-binding protein 1"
FT                   /id="PRO_0000081698"
FT   DOMAIN          11..89
FT                   /note="RRM 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   DOMAIN          99..175
FT                   /note="RRM 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   DOMAIN          191..268
FT                   /note="RRM 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   DOMAIN          294..370
FT                   /note="RRM 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   DOMAIN          542..619
FT                   /note="PABC"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00641"
FT   REGION          166..289
FT                   /note="CSDE1-binding"
FT   COMPBIAS        495..501
FT                   /note="Poly-Ala"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000244|PubMed:19413330"
FT   MOD_RES         299
FT                   /note="N6-methyllysine"
FT                   /evidence="ECO:0000269|Ref.7"
FT   MOD_RES         315
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648,
FT                   ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:23186163"
FT   MOD_RES         319
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         385
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000244|PubMed:24129315"
FT   MOD_RES         419
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000244|PubMed:24129315"
FT   MOD_RES         432
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000244|PubMed:24129315"
FT   MOD_RES         436
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000244|PubMed:24129315"
FT   MOD_RES         455
FT                   /note="Omega-N-methylated arginine; by CARM1; partial"
FT                   /evidence="ECO:0000305|PubMed:11850402"
FT   MOD_RES         460
FT                   /note="Omega-N-methylated arginine; by CARM1; partial"
FT                   /evidence="ECO:0000305|PubMed:11850402"
FT   MOD_RES         475
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P29341"
FT   MOD_RES         481
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000244|PubMed:24129315"
FT   MOD_RES         493
FT                   /note="Asymmetric dimethylarginine; alternate"
FT                   /evidence="ECO:0000244|PubMed:24129315"
FT   MOD_RES         493
FT                   /note="Dimethylated arginine; alternate"
FT                   /evidence="ECO:0000269|Ref.6, ECO:0000269|Ref.7"
FT   MOD_RES         493
FT                   /note="Omega-N-methylarginine; alternate"
FT                   /evidence="ECO:0000244|PubMed:24129315, ECO:0000269|Ref.6,
FT                   ECO:0000269|Ref.7"
FT   MOD_RES         506
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000244|PubMed:24129315"
FT   MOD_RES         512
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         518
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000244|PubMed:24129315"
FT   VAR_SEQ         447..535
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.5"
FT                   /id="VSP_009846"
FT   MUTAGEN         455
FT                   /note="R->A: Greatly reduces methylation by CARM1 (in
FT                   vitro); when associated with A-460."
FT                   /evidence="ECO:0000269|PubMed:11850402"
FT   MUTAGEN         460
FT                   /note="R->A: Greatly reduces methylation by CARM1 (in
FT                   vitro); when associated with A-455."
FT                   /evidence="ECO:0000269|PubMed:11850402"
FT   CONFLICT        211..213
FT                   /note="Missing (in Ref. 1; CAA68428)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        410
FT                   /note="M -> I (in Ref. 5; CAA88401)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        428
FT                   /note="I -> V (in Ref. 1; CAA68428)"
FT                   /evidence="ECO:0000305"
FT   STRAND          12..17
FT                   /evidence="ECO:0000244|PDB:4F02"
FT   HELIX           24..31
FT                   /evidence="ECO:0000244|PDB:4F02"
FT   HELIX           32..34
FT                   /evidence="ECO:0000244|PDB:4F02"
FT   STRAND          37..44
FT                   /evidence="ECO:0000244|PDB:4F02"
FT   TURN            46..48
FT                   /evidence="ECO:0000244|PDB:4F02"
FT   STRAND          51..61
FT                   /evidence="ECO:0000244|PDB:4F02"
FT   HELIX           62..72
FT                   /evidence="ECO:0000244|PDB:4F02"
FT   STRAND          83..86
FT                   /evidence="ECO:0000244|PDB:4F02"
FT   HELIX           92..96
FT                   /evidence="ECO:0000244|PDB:4F02"
FT   STRAND          100..105
FT                   /evidence="ECO:0000244|PDB:4F25"
FT   HELIX           112..119
FT                   /evidence="ECO:0000244|PDB:4F25"
FT   HELIX           120..122
FT                   /evidence="ECO:0000244|PDB:4F25"
FT   STRAND          125..133
FT                   /evidence="ECO:0000244|PDB:4F25"
FT   STRAND          136..146
FT                   /evidence="ECO:0000244|PDB:4F25"
FT   HELIX           148..158
FT                   /evidence="ECO:0000244|PDB:4F25"
FT   STRAND          161..163
FT                   /evidence="ECO:0000244|PDB:2K8G"
FT   STRAND          169..174
FT                   /evidence="ECO:0000244|PDB:4F25"
FT   HELIX           176..183
FT                   /evidence="ECO:0000244|PDB:4F02"
FT   HELIX           547..551
FT                   /evidence="ECO:0000244|PDB:3KUJ"
FT   HELIX           555..557
FT                   /evidence="ECO:0000244|PDB:3KUJ"
FT   HELIX           558..573
FT                   /evidence="ECO:0000244|PDB:3KUJ"
FT   TURN            575..577
FT                   /evidence="ECO:0000244|PDB:3KUJ"
FT   HELIX           578..585
FT                   /evidence="ECO:0000244|PDB:3KUJ"
FT   HELIX           590..598
FT                   /evidence="ECO:0000244|PDB:3KUJ"
FT   HELIX           600..619
FT                   /evidence="ECO:0000244|PDB:3KUJ"
FT   TURN            623..625
FT                   /evidence="ECO:0000244|PDB:1JGN"
FT   STRAND          628..630
FT                   /evidence="ECO:0000244|PDB:1G9L"
SQ   SEQUENCE   636 AA;  70671 MW;  2EB1B02A346132EE CRC64;
     MNPSAPSYPM ASLYVGDLHP DVTEAMLYEK FSPAGPILSI RVCRDMITRR SLGYAYVNFQ
     QPADAERALD TMNFDVIKGK PVRIMWSQRD PSLRKSGVGN IFIKNLDKSI DNKALYDTFS
     AFGNILSCKV VCDENGSKGY GFVHFETQEA AERAIEKMNG MLLNDRKVFV GRFKSRKERE
     AELGARAKEF TNVYIKNFGE DMDDERLKDL FGKFGPALSV KVMTDESGKS KGFGFVSFER
     HEDAQKAVDE MNGKELNGKQ IYVGRAQKKV ERQTELKRKF EQMKQDRITR YQGVNLYVKN
     LDDGIDDERL RKEFSPFGTI TSAKVMMEGG RSKGFGFVCF SSPEEATKAV TEMNGRIVAT
     KPLYVALAQR KEERQAHLTN QYMQRMASVR AVPNPVINPY QPAPPSGYFM AAIPQTQNRA
     AYYPPSQIAQ LRPSPRWTAQ GARPHPFQNM PGAIRPAAPR PPFSTMRPAS SQVPRVMSTQ
     RVANTSTQTM GPRPAAAAAA ATPAVRTVPQ YKYAAGVRNP QQHLNAQPQV TMQQPAVHVQ
     GQEPLTASML ASAPPQEQKQ MLGERLFPLI QAMHPTLAGK ITGMLLEIDN SELLHMLESP
     ESLRSKVDEA VAVLQAHQAK EAAQKAVNSA TGVPTV
//
